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SUMMARY 
Cardiovascular disease (CVD) is the leading cause of death in the world and is 
predicted to remain so. Vascular growth and regeneration is a critical process necessary to 
the successful recovery of ischemic cardiovascular injuries and diseases. Unfortunately, 
postnatal vascular growth is difficult to achieve especially in the case of geriatric 
individuals who are likely to suffer from multiple cardiovascular complications. Therefore, 
the goal of this dissertation is to use markers CD14 and CD31 to isolate a cell population 
directly from peripheral blood capable of inducing vascular growth and repair.  
We first sought to identify the lineage composition and expression profiles of 
isolated cells. To do this, we used flow cytometry do determine that the CD31+CD14+ 
population is enriched with injury repair blood cell lineages. Analysis of RNA expression 
revealed upregulation of hallmark angiogenic factors in CD31+CD14+ cells and 
upregulated arteriogenic expression in CD31+CD14- cells. Further in vitro assays using 
conditioned medium displayed that paracrine factors secreted from CD31+CD14+ cells 
increased endothelial function and migration. We further determined the in vivo 
effectiveness of both PB- CD31+CD14+ cells and PB- CD31+CD14- cells in a murine model 
of critical limb ischemia (CLI). Our results indicate that both the PB- CD31+CD14- cell 
and the PB- CD31+CD14+ cell therapies strongly induce reperfusion in mouse hindlimbs 
when compared to all other therapies. Furthermore, PB- CD31+CD14+, - CD31+CD14- and 
–CD31+ cell treatments are all significant to PBS at 14 days. Further histological analysis 
of tissues shows PB- CD31+CD14+ cells rapidly increased capillary formation at early time 
 xvii 
points and have limited vasculogenic potential while CD31+CD14- cells increased SMC 
coverage of perfused vessels. 
Our research confirms the highly angiogenic potential of PB- CD31+CD14+ cells. 
Furthermore, this research is the first to identify a cell population in PB-CD31+CD14- cells 
with strong therapeutic capability that circumvents the angiogenic process, primarily 
functioning through arteriogenesis. These insights are significant for the further 
development of effective cell therapies for cardiovascular disease. 
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CHAPTER 1 INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death in the world and 
accounted for $329.7 billion (14%) of global total health expenditures in 20141. The AHA 
estimates that the total costs of CVD will reach $1.1 trillion by 20351. Despite significant 
reductions in risk factors and improvements in the management of CVD, there remains a 
dearth of adequate treatments, particularly pertaining to diseases such a peripheral artery 
disease (PAD)2. 
Motivation 
PAD, a state of obstructed blood flow in any arteries excluding the coronary and 
intracranial vessels, afflicts approximately 12 million people in the US and > 200 million 
people worldwide3,4. The majority of those suffering from PAD are asymptomatic and as 
disease progresses, patients may eventually develop critical limb ischemia (CLI) which has 
a 1-year amputation and mortality rate of 20% and 40%, respectively, for individuals 
without revascularization options5-7. 
PAD prevalence and incidence are both positively correlated with age, increasing 
to 10% by age 60 and 20% by age 807,8. As the global life expectancy continues to increase, 
it is likely that PAD will become significantly more common in the future7. As such, it is 
imperative to continue to develop new and effective treatments for the management and 
repair of PAD. 
Specific Aims 
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It has been previously demonstrated that bone marrow (BM) and PB derived CD31+ 
cells are highly angiogenic and capable of inducing neovascularization in murine models 
of hindlimb ischemia9-11. However, given that CD31+ cells are heterogeneous, the question 
remains as to whether this population may be further enriched for the angiogenic, 
arteriogenic and/or vasculogenic cell fraction. The central hypothesis of this dissertation is 
that PB-CD31+ cells may be concentrated into a more effective therapy using the 
distinguishing marker CD14. The objective of this dissertation will be completed by testing 
the central hypothesis using the following aims. 
Specific Aim 1 
Characterize the expression of PB- CD31+CD14+/- cells and determine their 
neovasculogenic potential in vitro. 
Our hypothesis is that the CD14+ fraction of PB-CD31+ cells will retain the 
angiogenic phenotype. In this aim, we use FACS and flow cytometry sorting to isolate and 
identify our cell populations. We then used robust expression profiling tools such as 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) and RNA-
Sequencing (RNA-Seq) to determine gene expression and functional characteristics. The 
effects of each cell fraction on endothelial cells is then evaluated using functional and 
characteristic assays on HUVECs cultured in conditioned medium. 
Specific Aim 2 
Evaluate the therapeutic effects of PB- CD31+CD14+/- cells in vivo using a 
murine model of critical limb ischemia. 
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We hypothesize that the CD31+CD14+ fraction will strongly induce vascular 
growth through induction of angiogenesis. To test this hypothesis, a well-established 
hindlimb ischemia model was utilized to study the time course of limb perfusion in 
BALB/c nude mice. Laser Doppler perfusion imaging (LDPI) and histology were used to 
evaluate vascular growth and repair. 
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CHAPTER 2 LITERATURE REVIEW 
Peripheral Artery Disease 
Cardiovascular disease (CVD) is the leading cause of death in the world with 
Peripheral artery disease (PAD) attributing to 3.1% of fatal CVDs1. PAD occurs when there 
is an obstruction of blood flow in any arteries excluding the coronary and intracranial 
vessels and afflicts approximately 12 million people in the US and > 200 million people 
worldwide3,4. The majority of those suffering from PAD are asymptomatic and as disease 
progresses, patients may eventually develop critical limb ischemia (CLI) which has 1-year 
amputation and mortality rates of 20% and 40%, respectively, for individuals without 
revascularization options6,7. Among CLI patients that undergo treatment, only 25% will 
see their symptoms resolved after a year12. Unfortunately, intermittent claudication, which 
is the typical diagnostic method for detection of PAD, is absent in nearly 4/5th’s of 
patients5,13. PAD is also known to become progressively more prevalent with age with 
incidence rates increasing sharply around 65 years of age14. Furthermore, due to the 
increasing life expectancies, it is expected that the number of PAD patients will continue 
to increase4,15.  
Risk Factors and diagnosis 
Risk factors for PAD include hypertension, dyslipidemia, hyperhomocysteinemia, 
obesity, alcohol consumption, smoking, age, poor diet and lack of exercise1,7,14. Genetic 
factors such as gender and race are also important risk factors for PAD; for instance, 
increased incidence of PAD is found specifically in the African American and Hispanic 
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American populations when compared to the entire American populace1,16. PAD also tends 
to present with other comorbidities like diabetes mellitus, chronic kidney disease and 
hypercoagulable states.  
PAD is diagnosed using the ankle brachial index (ABI). This is measured by using 
a continuous-wave Doppler device and dividing the higher of the 2 systolic pressures at the 
dorsalis pedis and posterior tibial arteries in the feet and legs by the higher of the systolic 
pressures in the brachial artery of each arm. A normal ABI registers between 1.00 and 1.40. 
An ABI ≤ 0.90 indicates 90% sensitivity and 95% specificity for PAD13. An ABI between 
0.90 and 1.00, while not considered PAD, is correlated with a 10% - 20% increase in the 
rate of a cardiovascular event13. Abnormal ABI is also a strong indicator of coronary or 
cerebrovascular disease17,18. In fact, PAD is a risk factor for other cardiovascular 
diseases1,19. Unfortunately, nearly 50% of PAD patients are asymptomatic20. As a result, 
ABI measurement is recommended for all patients ≥ 65 years old or ≥ 50 years with a 
history of diabetes or smoking21-23. Although less precise, pedal pulse palpation is a 
secondary diagnostic tool and is sometimes used as a preliminary screening for PAD24. 
Pathophysiology 
PAD has been classified in numerous ways since the 1950’s beginning with the 
four Fontaine classifications (Table 1)25. However, given the variety of PAD presentation, 
these classifications were revised to delineate disease progression and classification based 
on symptomology26, logistic angiography27,28 and morphology29. Presently, The American 
College of Cardiology/American Heart Association Practice Guidelines defines the 
presentation of PAD using four categories: asymptomatic, claudication, CLI and acute limb 
 6 
ischemia (ALI)21. This current classification is a comprehensive international collaboration 
effort known as the Trans-Atlantic Inter-Society Consensus Document II (TASC II). Using 
this system, asymptomatic patients are individuals whose ankle brachial index is 
consistently below 0.90 but do not express other symptoms. As disease progresses, patients 
may begin to experience intermittent claudication or pain from physical exertion that 
typically subsides with resting, thus entering the claudication category12. CLI patients will 
report chronic ischemic rest pain, that will often present with ulcers and gangrene. ALI 
indicates a sudden and rapid decrease in limb perfusion that often threatens the viability of 
the limb. ALI may occur due to a local thrombosis or embolic event in a patient who was 
previously asymptomatic12.  
PAD describes a loss of vascular conductance in the peripheral arteries primarily 
through atherosclerosis and associated thrombosis. Atherosclerosis is a process where the 
buildup of cholesterol and other substances causes arteries to become hardened and narrow. 
These plaques continue to grow as infiltrating monocytes differentiate into macrophages, 
engulf the lipids within the plaque, and become foam cells30,31. Vascular smooth muscle 
cells (SMC) will also migrate to the plaque and synthesize extracellular matrix (ECM) 
forming a fibrous cap31. As the plaque continues to grow, the internal stresses exceed the 
material strength of the fibrous cap leading to plaque rupture31,32. A ruptured plaque 
exposes the underlying thrombogenic matrix to the blood, allowing circulating platelets to 
adhere and aggregate activating the coagulation cascade leading to atherothrombosis30,33. 
As the thrombus continues to grow, cross sectional area of the artery is reduced and blood 
flow is progressively restricted30.  
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Under healthy conditions, the body will attempt to increase blood supply to the 
affected limb through the activation of angiogenesis and arteriogenesis34. Once tissue 
damage has occurred, vascular remodeling, inflammation and various apoptotic pathways 
will be activated to facilitate repair34. Unfortunately, for patients with CLI, these healing 
processes are ineffective due to various compounding issues such as loss of angiogenic 
potential or the presence of other comorbidities34-36. CLI patients will often develop ulcers 
and gangrene due to ischemia and necrosis.  
Table 1. Fontaine classification for peripheral artery disease37. 
Stage I Asymptomatic arteriopathy 
Stage II Exercise-induced ischemia 
     Iia Intermittent claudication, pain during walking 
  Relief of symptoms when standing 
  Compensated disease: walking distance > 100 m 
     Ibis Decompensated disease: walking distance < 100 m 
Stage III Ischemia-driven symptoms at rest 
     IIIa Ankle Pressure Index > 50 mmHg 
     IIIb Ankle Pressure Index < 50 mmHg 
Stage IV Trophic ulcers and gangrene 
     Iva Limited gangrene 
     Ivb Extensive gangrene 
Role of Inflammation in Vascular Repair 
Inflammation is the initial response to injury within the body carrying out multiple 
functions including fighting infection, clearance of cellular debris, ECM remodeling and 
induction of neovascularization. The immune response begins with the recruitment of 
leukocytes to the affected region. After an injury, platelets and polymorphonuclear 
leukocytes (PMNs) form a blood clot. Proinflammatory cytokines such as tumor necrosis 
factor-a (TNFA) and interferon-g (IFNG) at the site of injury upregulate various adhesion 
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molecules that facilitate leukocyte adhesion38. Neutrophils infiltrate infected tissue where 
they begin to debride devitalized tissue and clear any infectious agents38,39. In the absence 
of continued stimuli for recruitment, the infiltration of neutrophils subsides within 2 – 3 
days. Residual neutrophils are then phagocytosed by monocyte-derived macrophages39. 
Adhesion and diapedesis of monocytes is facilitated primarily through the upregulation and 
activation of adhesion molecules such as the platelet-endothelial adhesion molecule-1 
(PECAM-1 or CD31) and endothelial-leukocyte adhesion molecule-1 (ELAM-1 or E-
selectin) through mechanical and chemical mechanisms40,41. As monocytes extravasate 
from the blood into the tissue they differentiate into activated macrophages. While the 
complete function of macrophages in wound repair is incompletely understood, it is known 
that activated macrophages function as antigen presenting cells, phagocytes and as 
important synthesizers of potent growth factors, cytokines and matrix modulation proteins. 
The fundamental role of macrophages in tissue repair and recovery has been exemplified 
in numerous studies where macrophage depletion/impairment led to lack of debridement 
and delayed fibrosis and wound closure42-44.  
Current Therapies and Limitations 
The first line of defense for PAD is management and prevention which focuses on 
the reduction of risk factors45,46. For example, physical exercise programs have been 
recommended to increase waking distance and for prognostic measures34,47. Exercise; 
however, may prove problematic as PAD patients have an exercise capacity of < 5 
metabolic equivalents48,49. Weight loss and abstinence from drinking have also been 
significantly associated with lower risk of PAD50,51. Smoking in particular is one of the 
major risk factors for PAD along with diabetes and other CVDs1,33. As a result, smoking 
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cessation has one of the strongest correlations with a decrease in the incidence and 
progression of PAD15,50,51. Unfortunately, reduction of risk factors largely depends on the 
patient’s own resolution. For instance, in a survey of 112 individuals, 71% reported a lack 
of regular exercise and < 14% had a measured their blood pressure within a year52. As a 
result, early PAD is often managed through pharmacological means. 
Pharmacological treatment for PAD is often a complicated task due to the likelihood 
of PAD patients to also exhibit comorbid CVDs that would negatively respond to 
treatment53. Furthermore, endovascular interventions, including angioplasty and stenting, 
are often subject to fracture, restenosis and thrombosis54. As a result, alternative therapies 
for treating ischemic diseases have recently centered around growth and regeneration of 
blood vessels in ischemic tissues through neovascularization.  
Neovascularization 
Neovascularization describes the general process of cardiovascular repair and 
regeneration. Neovascularization is presumed to occur through three distinct processes: 
angiogenesis, arteriogenesis and vasculogenesis55,56. The ultimate goal of any ischemia 
therapy is to induce or magnify the manifestation of any combination of these three 
processes. 
Angiogenesis 
Angiogenesis describes the formation of new blood vessels from preexisting 
vasculature. This process is initiated through the hypoxia inducible factor-1 alpha (HIF-
1a) which, in an oxygen deprived environment, binds to enhancer regions that upregulate 
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angiogenic genes such as the vascular endothelial growth factor (VEGF) signaling 
pathways57,58. VEGF increases vascular permeability through redistribution of platelet 
endothelial cell adhesion molecule-1 (PECAM-1 or CD31) and vascular endothelial-
cadherin (VE-cadherin or CDH5)59. The degree of vascular permeability is regulated by 
Angiopoietin-1 (ANGPT1) which reduces plasma leakage without affecting endothelial 
proliferation60. As endothelial cells migrate toward ischemic tissue, they begin to form 
cords. These cords will form lumens as endothelial cells thin and anastomose. The growth 
of this nascent vasculature is  encouraged and supported by recruited macrophages61,62. 
Hypoxia recruits inflammatory cells that release cytokines and chemokines that stimulate 
endothelial migration and sprouting (Figure 1A)63. 
Vasculogenesis 
Vasculogenesis is the process of de novo blood vessel growth or the differentiation 
of a progenitor population into new endothelial cells to form or contribute to a vascular 
network64. This process happens within the embryo when mesodermal cells differentiate 
into hemangioblast cells that, in turn, differentiate into angioblasts and eventually 
endothelial cells65. The vasculogenic potential of adults is severely limited; however, there 
remains a small population of endothelial progenitor cells (EPCs) capable of recruiting 
from the bone marrow to a site of injury, differentiating into endothelial cells and 
incorporating into the vasculature (Figure 1B)66,67.  
Arteriogenesis 
Arteriogenesis refers to the maturation of pre-existing collateral arteries increasing 
vascular conductance. Unfortunately, the details of this process are not yet fully 
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understood. The accepted premise is that altered flow conditions and circumferential wall 
stresses trigger proliferation of vascular SMCs and induce “muscularizaton” of the nascent 
vasculature where they begin to expand and contract, thereby increasing the diameter of 
the lumen as shown in Figure 1C58,68. After a significant stenosis has occurred in a major 
artery, the blood is redirected to the path of least resistance through preexisting arterioles. 
This increased shear stress activates the endothelial cells to release nitric oxide and 
cytokines such as monocyte chemoattractant protein-1 (CCL2), granulocyte-macrophage 
colony stimulating factor (GM-CSF) and adhesion molecules such as selectins, 
intercellular adhesion molecules (ICAM1 and ICAM2), and vascular cell adhesion 
molecules (VCAMs)59,69,70. These secreted cytokines stimulate integrin expression on 
circulating monocytes which then bind to the activated adhesion molecules present on 
endothelial cells, allowing migration through the vascular wall69. Recruited monocytes will 
then differentiate into macrophages and secrete various extracellular matrix (ECM) 
proteins, proteoglycans and proteases to remodel the microenvironment59,71. Inflammatory 
cells secrete multiple growth factors, in particular those from the fibroblast growth factor 
(FGF) family, to induce endothelial and SMC migration and proliferation. This 
proliferation is supervened by the migration of SMC into the vessel wall to form a 
neointima. These SMCs, along with local and recruited fibroblasts and macrophages, 
remodel the vessel through the secretion of ECM enzymes such as matrix 
metalloproteinases (MMPs) and plasmin in order to provide more space for additional cell 
layers59,69. The increased diameter of the remodeled vessel reduces fluid shear stress which 
then signals vascular maturation. Furthermore, the initial thinning of the vascular wall 
increases circumferential wall stress which is a proliferative stimulus for SMCs. The 
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proliferation of SMCs acts as a negative feedback to normalize the circumferential wall 
stress and end vascular remodeling. 
Molecular Therapies for CLI 
There have been several angiogenic growth factors investigated as therapies for 
ischemic cardiovascular disease including VEGF, FGF, hepatocyte growth factor (HGF) 
and HIF-172-75. A variety of clinical trials have been conducted using VEGF to treat limb 
ischemia74,76-78. Overall, treatment with VEGF has largely proven ineffectual with treated 
patients having very modest gains. A potential cause for this lack of recovery is that VEGF, 
while a potent and effective stimulator of endothelial proliferation and vascular growth, is 
only capable of inducing immature, leaky, unstable vessels79. There were a few attempts 
to use HIF-1, the transcription factor that precedes the angiogenic cascade; however, the 
results of the trials were underwhelming in that there was no significand difference between 
treatment and placebo groups73,80. Other trials using FGFs have reported similarly modest 
results81-83. One such study was stopped prematurely due to clinically significant 
proteinurea81. As a result, future clinical trials developed delivery strategies to mitigate the 
side-effects of FGF administration72. HGF has been shown to increase the ABI in PAD 
patient with little to no side effects of gene therapy75,84,85. These benefits have shown some 
promise in translating to CLI86. Overall, the use of growth factors to treat limb ischemia 
have been largely ineffective leading to thoughts that a combination of factors may be 
necessary. One solution is to use cells as a growth factor releasing vessel that responds to 
the microenvironment. 
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Cell Therapies for CLI 
Endothelial Progenitor Cells 
 The discovery of a population of peripheral blood CD34+ cells by Asahara et al. 
(1997) established the existence of EPCs that can differentiate ex vivo into ECs66. 
Classically, EPCs are identified through expression of both stem (such as CD133) and 
progenitor markers (such as KDR; kinase insert domain receptor)87. In culture, EPCs have 
been shown to form early-outgrowth and late-outgrowth colonies66,67. Early outgrowth 
cells express hematopoietic lineage markers and are clearly angiogenic but do not give rise 
to endothelial cells; however, late outgrowth cells show a similar cell morphology, 
proliferation rate and surface marker expression to ECs and lack hematopoietic lineage 
markers88,89. The application of EPCs to therapeutic approaches however, has been limited 
ArteriogenesisAngiogenesis
Vasculogenesis
EC sprouting
Recruitment Incorporation
SMCEPC
Angiogenic
Factor 
Release
Remodeling
&
SMC Recruitment
Figure 1. Schematic depicting the three major processes of neovascularization. (A) 
angiogenesis, (B) vasculogenesis and (C) arteriogenesis. 
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by their broad definition, and the lack of standardized methods for isolation and culture90,91. 
As a result, clinical trials using EPCs for cardiac and vascular repair have been performed 
using the parent population of bone marrow (BM) and peripheral blood derived 
mononuclear cells (MNC) or subsequently sorted CD34+ cells under the premise that EPCs 
are a subpopulation of transplanted cells92,93. Other proposed parent populations of EPCs 
include CD31+ cells and CD14+ cells10,94. CD14+ cells have been tested in clinical trials 
with limited success95. Clinical trials using EPCs have consistently shown statistically 
significant improvements in vascular perfusion, infarct reduction, and transcutaneous 
oxygen pressure (TcPO2) levels in patients; however, vascular improvements remain 
modest96-99. The underwhelming performance of EPCs in clinical trials can likely be 
attributed to a reduction in the proliferative, migrational and functional capacity of EPCs 
associated with cardiovascular disease, aging and smoking100-102. EPCs are also a rare 
population of cells accounting less than one for every 10,000 MNCs103,104. 
Mesenchymal Stem Cells 
MSCs have been investigated as potential candidates for stem cell therapy due to 
their angiogenic gene expression, immunosuppressive effects, and transdifferentiation 
potential105,106. Studies have shown that MSCs can differentiate into adipocytes107,108, 
chondrocytes108-110, osteoblasts108,111, myocytes112, neural cells113 and endothelial cells114. 
However, there remains questions about the differentiation capacity of MSCs outside of 
the adipogenic, chondrogenic and osteogenic lineages115,116. Furthermore, MSCs have been 
shown to form tumors and promote tumor growth after transplantation into animal 
models117-119. In clinical trials, MSCs have demonstrated significant trends toward 
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increased cardiac output, muscle mass, and wound healing; however, their therapeutic 
effects remain marginal120-122.  
Overall, while the use of adult stem cells, including EPCs and MSCs, in clinical 
trials has been shown to collectively decrease limb amputation and increase amputation 
free survival of critical limb ischemia patients, the effects have been marginal123.  
Effector cells (CD31+ cells) 
CD31+ (PECAM-1+) cells are highly angiogenic and vasculogenic cells found in 
the bone marrow and circulating in peripheral blood9. As the major mechanisms underlying 
therapeutic effects for BM-derived stem and progenitor cells were determined to be largely 
paracrine effects, Kim et al. identified a cell population enriched for the angiogenic 
fraction9,10. Furthermore, direct isolation using a surface marker circumvented negative 
phenotypic changes associated with in vitro culture and the use of animal serum. Isolation 
of CD31+ cells directly from BM were shown to exclusively exhibit hematopoietic stem or 
progenitor cell activities without the need for expansion in vitro10,11. Furthermore, CD31+ 
cells were enriched for both angiogenic and vasculogenic cells, displaying spontaneous 
tube formation in vitro and incorporation into host vasculature in vivo10,11,124. It was 
recently shown that spherical culture of myeloid cells produces highly angiogenic 
CXCR4+CD31+ clusters125. These angiogenic cell clusters contained many cells double 
positive for CD14 and CD31125. 
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CHAPTER 3 IDENTIFICATION AND CHARACTERIZATION OF 
PERIPHERAL BLOOD MONONUCLEAR CELL FRACTIONS 
Introduction 
Ischemic cardiovascular disease (CVD) is the leading cause of death in the United 
States1,126. Unfortunately, the current medical therapies used to treat CVD are often only 
effective at slowing disease progression and relieving symptoms of underlying 
disease53,54,127. Peripheral artery disease (PAD) treatment often will require the 
administration of multiple therapies in combination; however, this may become 
problematic with the limited tools available for treating CVD128-130. The major cause of 
ischemic CVD is atherosclerosis, which leads to atherothrombus formation and the 
occlusion of arteries12,30. The body will attempt to increase blood supply to the affected 
limb through the activation of angiogenesis and arteriogenesis; however, for patients with 
CLI, these healing processes are ineffective due to various compounding issues such as 
loss of angiogenic potential or the presence of other comorbidities34-36.  
Angiogenic Cells for Cardiovascular Disease 
For the past few decades, cell therapy has been investigated as a potential solution to 
inducing angiogenesis and vascular repair. For example, endothelial progenitor cells 
(EPCs) have been extensively investigated for their angiogenic potential90,131,132. EPCs 
have consistently displayed strong secretion of angiogenic growth factors such as VEGFA, 
FGF, HGF and CXCL12133. Given that EPCs originate out of the mononuclear cell (MNC) 
population, MNCs have also been shown to express angiogenic factors to a lesser extent. 
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Similarly, mesenchymal stem cells (MSC) have been investigated as a promising 
proangiogenic cell due to their expression of angiogenic factors VEGF, FGF2, and 
ANGPT1134,135 . Recently, bone marrow (BM) and peripheral blood (PB) CD31+ cells have 
been investigated for their highly angiogenic expression10,11. CD31+ cells have been 
demonstrated to be enriched with multiple proangiogenic factors such as VEGFA, HGF, 
FGF2, CCL2, ANGPT1, insulin-like growth factor 1 (IGF1) and platelet derived growth 
factor beta (PDGFB)11,124. The angiogenic effects of these various cells has been 
extensively investigated and characterized; however, each cell population, while 
angiogenic, also has shortcomings toward its application to treat CVD in humans. 
The application of EPCs is limited by their broad definition, and the lack of 
standardized methods for isolation and culture90,91. As a result, clinical trials using EPCs 
for cardiac and vascular repair have been performed using the parent population of BM 
and PB derived MNCs or subsequently sorted CD34+ cells under the premise that EPCs 
are a subpopulation of transplanted cells92,93. Furthermore, EPCs are an extremely rare 
population of cells accounting less than 100 parts per million MNCs103,104. In the case of 
MSCs, a number of claims have been made about their angiogenic potential, vasculogenic 
capability, immune privileged nature and other bold claims; however, it is well documented 
that MSCs are indistinguishable from fibroblasts136. MSCs also suffer from a lack of 
consensus in the literature defining their expression and characterization137. Furthermore, 
one of the criteria critical to the identification of MSCs requires their maintenance in 
culture, which is known to have significant transcriptional consequences as early as 
passage 0136,138. CD31+ cells show great promise as an angiogenic cell therapy with 
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vasculogenic potential; however, given their heterogeneous nature, it is unclear if this 
population of cells may be further enriched for proangiogenic cell types.  
CD14 for the Enrichment of PB-CD31+ Cells 
It was reported that approximately 40% of CD31+ cells also express CD1411. CD14 
is a differentiation antigen expressed by monocytes, macrophages and activated 
granulocytes; however, in the case of PB-CD31+ cells, CD14 is a monocyte marker139. This 
may be concluded since macrophages are, in part, defined by their location within tissue 
and derivation from circulating monocytes140. Granulocytes are removed in the process of 
MNC isolation from whole blood141. Monocytes are known to be critical to the angiogenic 
process with important functions in growth factor secretion, matrix remodeling and 
clearance of debris71,142. Monocytes have also been proposed as the true phenotype of EPCs 
in circulation94,132. However, there exists some controversy over the contribution of 
circulating monocytes to the proinflammatory, anti-healing M1 phenotype of 
macrophages143-145. Furthermore, in a CD14 knockout mouse, it was shown that diabetic 
mice had reduced adiposity, lower blood pressure and improved glucose homeostasis146. 
For this thesis, we investigated the angiogenic potential of PB- CD31+CD14+ cells. 
We hypothesized that the CD14+ population of PB-CD31+ cells would contain the more 
angiogenic subset of cells. Using rigorous characterization methods, we demonstrate that 
PB- CD31+CD14+ cells are indeed the highly angiogenic subfraction of PB-CD31+ cells. 
We also uncovered a highly arteriogenic population of cells in the PB- CD31+CD14- 
fraction. Our results uncover two independent populations of cells with high therapeutic 
potential for cardiovascular regeneration. 
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Methods 
Isolation and culture of PB cells.  
Human PB samples were collected from healthy male and female volunteers. 
Isolation of MNCs was performed using a modification of a previously reported method147. 
Briefly, each PB sample was diluted with one volume of calcium- and magnesium-free 
phosphate-buffered saline (PBS) containing 2% bovine serum albumin (Miltenyi Biotec, 
Auburn, California), layered on one volume of Histopaque-1077 (Sigma, St. Louis, 
Missouri), and centrifuged at 400 g for 35 min. The MNCs were harvested from the 
interface and washed with magnetic-activated cell sorting (MACS) buffer (Miltenyi 
Biotec). MNCs were centrifuged again at 400 g for 10 min to remove platelets. The cells 
were counted and resuspended in MACS buffer blocking reagent.  
For FACS isolation, cells were incubated for 20 min at 4°C with phycoerythrin 
(PE)-conjugated mouse anti-human CD14 and fluorescein isothiocyanate (FITC)-
conjugated mouse anti-human CD31 antibodies (BD Bioscience, San Jose, California). 
Proper isotype-identical immunoglobulin G (IgG) served as controls. For MACS isolation, 
human CD14 microbeads (Miltenyi Biotec) were sequentially added and incubated at 4°C 
for 20 min. The cells were washed and resuspended in MACS buffer. CD14+ and CD14– 
cells were isolated using magnetic LS columns (Miltenyi Biotec) according to the 
manufacturer’s instructions. CD14- cells were then washed with MACS buffer and 
incubated with Human CD31 microbeads (Miltenyi Biotec) at 4°C for 20 min. 
CD31+CD14- and CD31- cells were isolated using magnetic LS columns (Miltenyi Biotec) 
according to the manufacturer’s instructions.  
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For conditioned medium experiments, PB cells were plated at a density of 1 × 106 
cells/cm2 on 0.1% fibronectin in endothelial basal media 2 supplemented with 2% or 0.5% 
fetal bovine serum (Lonza Cologne AG, Cologne, Germany), and incubated at 37°C in 5% 
CO2.  Conditioned medium was collected after 24 h, centrifuged and sterile filtered through 
a 0.22 um filter. Human umbilical vein endothelial cells (HUVEC) were plated at a density 
of 1 × 106 cells/cm2 on 0.1% gelatin coated plates. HUVECS were cultured in endothelial 
growth media 2 supplemented with 15% fetal bovine serum and the cytokine cocktail, 
SingleQuots (Lonza Cologne AG, Cologne, Germany) and incubated at 37°C in 5% CO2.  
Media was changed after 24 h and every 2 to 3 days. Cells were detached by incubation 
with 0.05% trypsin–ethylenediamine tetraacetic acid (Gibco, Gaithersburg, Maryland) for 
5 min at 37°C. When the cells reached 70% confluence, they were either passaged, used in 
other assays, or frozen in freezing media (90% fetal bovine serum and 10% dimethyl 
sulfoxide) for future use. 
Flow cytometry.  
PB-MNCs were resuspended in PBS and incubated for 20 min at 4°C with direct 
phycoerythrin-, R-phycoerythrin-cyanine 5 (PE-Cy5)- or fluorescein isothiocyanate 
(FITC)–conjugated antibodies or nonconjugated antibodies followed by a FITC-
conjugated rabbit anti-mouse IgG. Proper isotype-identical IgG served as controls. After 
staining, the cells were fixed in 2% paraformaldehyde and analyzed on a flow cytometer 
(Becton Dickinson, San Jose, California). Antibodies used included the following: CD3, 
CD4, CD8, CD11b, CD11c, CD14, CD16, CD19, CD31, CD34 (all from BD Bioscience, 
San Jose, California), CD56 (R&D Systems, Minneapolis, Minnesota) and CD133 
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(AC133; Miltenyi Biotec). Flow cytometric data were analyzed with FlowJo (Tree Star, 
Inc., Ashland, Oregon) using appropriate isotype-matched controls. 
qRT-PCR.  
Total RNA from PB-MNCs, -CD14+CD31+ cells, -CD31+CD14- cells, -CD31+ cells 
and -CD31- cells was isolated using RNeasy Plus Mini Kit (Quiagen, Hilden, Germany) 
according to manufacturer’s instructions. Extracted RNA was reverse-transcribed using 
Taqman Reverse Transcription Reagents (Applied Biosystems, Foster City, California) 
according to manufacturer’s instructions. The complimentary DNA was subjected to qRT-
PCR using human-specific primers and probes (Table 3). Quantitative assessment of RNA 
levels was performed using an ABI PRISM 700 Sequence Detection System (Applied 
Biosystems). Housekeeping gene human large ribosomal protein P0 (RPLP0) was used as 
an internal expression control. Relative gene expression was calculated using the ∆∆Ct 
method with the MNC parent population as the standard. It is recommended that our qRT-
PCR data be analyzed using a non-parametric statistical method due to the low sample size 
and generally high variability within our samples; however, we opted to use ANOVA and 
Tukey’s post hoc analysis due to their general robustness to normality. The intention of our 
qRT-PCR analysis is to determine if the mean of one population of cells is generally higher 
or lower than that of the others. In this regard, ANOVA and Tukey’s post hock perform 
adequately.  
RNA-Seq 
Total RNA from PB-MNCs, -CD31+CD14+ cells, -CD31+CD14- cells, -CD31+ cells and -
CD31- cells was isolated using RNeasy Plus Mini Kit (Quiagen, Hilden, Germany) 
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according to manufacturer’s instructions. 50 µl at 20 ng/µl of RNA per sample was 
sequenced using Illumina sequencing technology (Macrogen, Seoul, South Korea). Raw 
fastq files were analyzed using the open-source, web-based platform Galaxy 
(usegalaxy.org). Raw data files were uploaded to the Galaxy server and quality controls 
were generated using FastQC All samples were found to be of high quality so no truncation 
of reads was necessary (Figure 2). Sequences were aligned using the hierarchical indexing 
for spliced alignment of transcripts 2 (HISAT2) system. Count files were generated using 
gene transfer files for Genome Reference Consortium human genome build 38 (GRCh38) 
available from gencodegenes.org and the high throughput sequencing (HTSeq) Python 
package. Further analysis of count files was done in R programming (Figure 25). 
Differential gene expression was determined using the Protein ANalysis THrough 
Evolutionary Relationships (PANTHER) classification system148,149. A statistical 
overrepresentation test was used to determine ontological significance of differentially 
expressed gene list using the PANTHER method of comparing the percent representation 
of a particular PANTHER category in a reference/test list to the experimental list. 
PANTHER uses a binomial comparison test to determine significant representation of a 
given gene ontology category.  
GSEA Analysis.  
We used the gene set enrichment analysis (GSEA) software from the Broad Institute 
to analyze significant enrichment of gene sets between groups. A priori gene sets were 
taken from the Broad Institute gene ontology database and used to perform GSEA between 
peripheral blood cell fractions. 
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Wound healing assay 
The endothelial wound healing assay was done by plating HUVECs between 
passage 5 and 7 on gelatin-coated 12-well plates at a density of 1 x 105 cells / cm2 in 
endothelial growth media 2 supplemented with 15% fetal bovine serum and the cytokine 
cocktail (EGM-2), SingleQuots (Lonza Cologne AG, Cologne, Germany) and incubated at 
37°C in 5% CO2. After 24 hrs, media was changed to endothelial basal media 2 
supplemented with 0.5% fetal bovine serum (0.5% EBM-2) and incubated overnight at 
37°C in 5% CO2. Plates were imaged to confirm confluency and health of the cells. A 200 
µl sterile pipette tip was scraped vertically from bottom to top across the 12-well plate 
through the confluent monolayer of cells to create a uniform cell-free zone. Immediately, 
Figure 2. Representative quality control report for RNA sequencing 
data. 
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the wells were gently rinsed with PBS to remove cell debris and old media. Conditioned 
medium was added to each treatment group and EGM-2 and 0.5% EBM-2 were used as 
positive and negative controls, respectively. 
Tube forming assay 
Growth factor reduced (GFR) Matrigel was thawed overnight at 4°C. Chilled 96-
well plates were placed on ice and chilled pipette tips were used to pipette 50 µl of Matrigel 
in each well. Matrigel was allowed to polymerize for 30 min in an incubator at 37°C in 5% 
CO2. HUVECs between passage 5 and 7 were suspended in 2% EBM-2, EGM-2, or 
conditioned medium and layered on top of the Matrigel at 1 x 104 cells per well. Each well 
was imaged following 6 hrs incubation at 37°C in 5% CO2. Tube formation was analyzed 
in ImageJ using the Angiogenesis Analyzer tool (Figure 3). 
Statistical Analysis 
Figure 3. Representative image of Angiogenesis Analyzer overlay in ImageJ. 
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All data are represented as means ± S.E.M and statistical analysis was conducted 
in R (Figure 27). Student’s t test was used for the statistical analysis for continuous 
variables between two groups and ANOVA followed by Tukey-Kramer or Fisher least 
significant difference (LSD) method for variables among more than 2 groups. A p value < 
0.05 was considered statistically significant. 
Results 
CD14+ cells are contained exclusively within the CD31+ fraction of cells. 
We used FACS analysis to isolate each cell fraction. The gating system we used 
was as follows: 1) use the side scatter (SSC) and forward scatter (FSC) area channels to 
remove cellular debris from our target population; 2) use that slection and used the FSC 
height and FSC area channels to remove doublets and triplets from the selection; gate for 
cells based on their fluorescnce intensity of CD14- and CD31-conjugated fluorophores. 
The scatterplot of single MNCs shows that all PB-CD14+ cells are also positive for CD31 
(Figure 4A). This result is consistent with the literature where CD14 was not detected in 
the PB-CD31- population of cells11. We used this data to develop a MACS sorting protocol 
for isolation of cells positive for both CD14 and CD31 using the scheme depicted in Figure 
4B. The MACS sorting procedure is more crude and prone to lower sorting purity that 
FACS so we used flow cytometry to determine the sorting efficiency and purtiy of MACS 
sorted cells. Flow cytometric analysis on MACS sorted cells shows that > 95% of MACS 
isolated CD14+ cells and < 2% of CD14- cells express CD14. Similarly, > 95% of  MACS 
sorted CD31+ cells express CD31 (Figure 4C). Notably, just under 12% of MACS sorted 
CD31- cells express CD31 indicating a loss of sorting efficiency when using MACS. While 
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positive selection using MACS results in high purity of isolated populations, there is still 
potential contamination of CD31+ cells in the flowthrough after MACS sorting using CD31 
microbeads. We concluded that these contaminating CD31+ cells lowly express CD31 and 
are such a minor portion of the CD31- population that they would not significantly alter the 
function of the population as a whole; however, in order to avoid the introduction of any 
artifacts in our evaluation, we used FACS sorted cells for all in vitro assays. 
CD31+CD14+ cells are enriched with stem and vascular repair blood lineages 
Given the heterogeneity of PB cells, it is important to determine which cell lineages 
remain present in each isolated cell fraction. This information is important for deducing 
how each cell fraction is likely to function during injury repair. We decided to use lineage 
markers for T-cells (CD3), T-helper cells (CD4), cytotoxic T-cells (CD8), monocytes 
(CD11b and CD16), dendritic cells (CD11c), B-cells (CD19), natural killer cells (CD56) 
and hematopoietic stem and progenitor cells (HPSC) (CD34 and CD133). These lineages 
together constitute the mononuclear cell portion of leukocytes and all have a unique role 
in injury and cardiovascular repair150. In particular, T-cell recruitment and polarization 
plays an important role in macrophage polarization and cell clearance while B-cells initiate 
and facilitate the T-cell immune response and humoral immunity151-153. Dendritic cells 
modulate the immune response while monocytes differentiate into macrophages and aid in 
tissue clearance, remodeling and wound healing39,150,154. Using flow cytometry to 
determine lineage expression we determined PB-CD31+CD14+ cells were significantly 
enriched with expression of monocyte markers CD11b, CD16, and HPSC marker CD34 
when compared to all other cell fractions cells. PB-CD31+CD14+ cells were also highly 
enriched for dendritic cell marker CD11c and HSPCS marker CD133 compared to all other 
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cell populations except PB-CD31+ cells (Figure 5). Markers indicative of T-cell and B-cell 
lineage were not significantly different between cell fractions. However, CD56, a marker 
for natural killer cell lineage, was significantly lower in the PB-CD31+CD14+ cell 
population than in the PB-CD31- fraction. While the enrichment of monocyte markers 
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CD14 and CD31. (B) MACS isolation procedure of PB-MNCs. (C) MACS sorting 
efficiency. n = 3. 
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within the PB-CD31+CD14+ fraction is expected, enrichment of dendritic cell marker 
CD11c implies a potential immunomodulatory function. Furthermore, the 
overrepresentation of the HSPC markers CD34 and CD133 imply that if a progenitor cell 
population is to be isolated, it would be found in the PB-CD31+CD14+ population of cells. 
We next used flow cytometry to determine the representation of CD31+CD14+ and 
CD31+CD14- cells within various cell lineage groups. CD41-CD31+ cells were more highly 
represented in the T-cell (CD3) fraction compared to CD31+CD14+ cells. The B-cell 
(CD19) and HSPC (CD34 and CD133) populations were shown to have a significant 
portion of cells with CD31+CD14+ expression (Figure 6). The observation that roughly 
75% of PB-CD34+ and CD133+ cells are CD31+CD14+ further supports the idea that 
circulating progenitor cells are contained within the PB-CD31+CD14+ fraction.  
PB-CD31+CD14+ cells and PB-CD31+CD14- cells express angiogenic and arteriogenic 
factors, respectively.  
We then used RT-PCR to determine differences in mRNA expression between groups. In 
order to accurately compare gene expression, it is necessary to use a reference gene that is 
constitutively expressed at a similar level for all sample groups. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) is by far the most commonly used gene for these 
studies; however, there have been conflicting studies about the suitability of GAPDH as an 
internal reference control155-157. In order for a gene to be considered suitable as a standard, 
it must have a standard deviation of less than 1158. We chose to compare two genes, 
GAPDH and human large ribosomal protein P0 (RPLP0) as they have both been indicated 
as suitable housekeeping genes for hematopoietic cells155,157. We first compared the Ct 
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value of RPLP0 and GAPDH for every cell fraction using peripheral blood from three 
donors/samples (Figure 7A). Notably, we see variations in both genes across all samples 
except for RPLP0 in Sample B. Interestingly, there is a consistent trend in the GAPDH 
expression implying a relative difference in expression specific to each cell fraction. When 
we determined the standard deviation of each gene across all PB cell fractions, we found 
that RPLP0 and not GAPDH was consistently below a standard deviation of 1 (Figure 7B). 
Figure 7C shows that GAPDH expression is highly variable from donor to donor when 
RPLP0 is used as the internal standard. As a result, we chose RPLP0 as our reference gene 
for our qRT-PCR studies. These studies also demonstrate the importance of first 
normalizing the expression of each cell population to a control population (i.e. the MNC 
population) before pooling data from different donors/samples due to the differing baseline 
expression of the reference gene from donor to donor. 
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In order to determine the expression profiles of PB- CD31+CD14+/- cells we used 
qRT-PCR analysis for angiogenic, arteriogenic and immunogenic growth factors, 
cytokines and enzymes. Hallmark angiogenic factors VEGFA and HGF were significantly 
upregulated in PB-CD31+CD14+ cells compared to PB-CD31+CD14- cells and CD31- cells. 
Similarly, PB-CD31+ cells had increased expression of VEGFA and HGF compared to PB-
CD31- and CD31+CD14- cells, respectively. Expression of IGF was markedly low in PB-
CD31+CD14+ cells compared to other groups; however, this difference was not significant. 
PB-CD31+CD14+ cells and PB-CD31+ cells displayed higher expression of angiogenic 
factors ANGPT1 and CXCL8 compared to PB-CD31+CD14- cells and PB-CD31- cells 
although these differences in expression were not significant (Figure 8). 
Arteriogenic factor PDGFB was significantly highly expressed in both PB-
CD31+CD14- cells and PB-CD31- cells compared to PB-CD31+CD14+ cells and PB-CD31+ 
cells. Furthermore, ECM remodeling enzyme MMP2 was significantly expressed in PB-
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CD31+CD14- cells compared to all other cell fractions. Interestingly, Arteriogenic factor 
FGF2 appeared to have reduced expression in the CD31+CD14+ cell fraction while CCL2 
showed higher expression although these differences were not significant (Figure 9). 
Among immune response regulatory cytokines, interleukin 10 (IL10) appeared to 
show higher expression in the PB-CD31+CD14+ and PB-CD31+ populations and cytokine 
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IFNG appeared to show higher expression in the PB-CD31+CD14- and PB-CD31- 
populations however these differences in expression were not significant (Figure 10). The 
observed expression profiles imply a pro-angiogenic secretion profile for both PB-CD31+ 
and PB-CD31+CD14+ cells and a pro-arteriogenic secretion profile for PB-CD31+CD14- 
cells. 
PB-CD31+CD14+ cells have highly correlated gene expression with PB-CD31+ cells. 
In order to investigate the full expression profile of each cell fraction, we used 
RNA-Seq. Total RNA from each cell group was isolated, sequenced and analyzed for 
expression of angiogenesis and immune related genes. The gene sets used for analysis of 
expression correlation were the gene ontology (GO) angiogenesis (279 genes) and GO 
Immune response (1075 genes) gene sets. A scree plot was generated to show the variances 
among calculated components of the sequencing data. As shown in Figure 11A, the 
contribution of variance from each eigenvector clearly begins to level between components 
2 and 3. We decided to determine population groupings along the primary (PC1) and 
secondary (PC2) principal components in order to account for 70% of the variance in the 
data. A principal component analysis plot of population groupings among angiogenic and 
inflammatory genes reveals that PB-CD31+CD14+ cells are highly correlated with PB-
CD31+ cells along PC1 while PB-CD31+CD14- cells are more similar to PB-CD31+ cells 
along PC2 (Figure 11B). Furthermore, PB-CD31+CD14+ and -CD31+CD14- cells are 
dissimilar from each other along both PCs and the same is true for the PB-CD31+ and -
CD31- populations. Most of the variance within the data is found along PC1, showing a 
stronger correlation between PB-CD31+CD14+ and -CD31+ cells than between PB-
CD31+CD14- cells and -CD31+ cells. The PB-CD31+ population has strong correlation 
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along both PCs showing that angiogenic and immune genes are highly expressed in this 
population. The distribution of cells within the plot show that the CD31+CD14+ and 
CD31+CD14- subpopulations completely split relative expression of these correlated genes 
Figure 8. qRT-PCR analysis for angiogenic growth factors and cytokines. * p < 
0.05, ** p < 0.01. n = 3. 
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with many angiogenic and immune response genes most highly expressed within the 
CD31+CD14+ fraction. 
Using R, we generated a heatmap where the angiogenic and immune response genes 
were ordered from high expression in PB-CD31+ cells to high expression in PB-CD31- 
cells (Figure 12). Interestingly, the dendogram confirms the strong correlations between 
the PB-CD31+CD14+ and PB-CD31+ populations through their similar expression patters. 
Similarly, the PB-CD31+CD14- and PB-MNC populations are more closely related while 
the CD31- population is most different from all other populations. This data implies that 
the highly angiogenic features previously published about PB-CD31+ cells would still be 
retained within the PB-CD31+CD14+ fraction. 
To determine differentially expressed (DE) genes between PB-CD31+CD14+ and 
PB-CD31+CD14- cells we used the following pre-established gene ontology datasets 
available from the Broad Institute website: angiogenesis (279 genes), endothelial 
differentiation (67 genes), protein secretion (95 genes), cell-cell adhesion (604 genes), cell-
matrix adhesion (105 genes), and immune response (1075 genes). We combined the protein 
secretion and cell-cell adhesion gene sets into the broader cell signaling expression 
category. Likewise, the angiogenesis, endothelial differentiation, cell-matrix adhesion and 
immune response gene sets were relabeled as angiogenic, vasculogenic, cell migration and 
immunogenic gene categories, respectively. Out of the total list of 2225 genes, we found 
630 genes to be differentially expressed between the PB-CD31+CD14+ group and the PB-
CD31+CD14- group (Figure 13A). The PB-CD31+CD14+ fraction had increased expression 
in 42 angiogenic genes and lower expression in 36 genes when compared to PB-
CD31+CD14- cells. Among inflammation related genes, 172 were significantly upregulated 
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in the CD31+CD14- population while 116 genes were upregulated in PB-CD31+CD14+ 
cells. Genes related to endothelial differentiation and cell communication were nearly 
equally upregulated in both cell populations with 9 angiogenic genes upregulated in both 
populations and  112 and 109 cell communication genes upregulated in PB-CD31+CD14+ 
and PB-CD31+CD14- cells, respectively (Figure 13B). The expression distribution from 
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these gene ontology groupings display how both cell fractions are involved each of the 
various aspects of vascular regeneration and tissue repair; however, the specific expression 
signatures of these populations will provide greater insight into the mechanisms through 
which each of these populations primarily acts. 
PB-CD31+CD14+ cells significantly differentially express pro-angiogenic genes 
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In order to investigate potential mechanisms through which the PB-CD31+CD14- 
and PB-CD31+CD14+ cell fractions function, we created a list of the top 50 most 
differentially expressed genes for each group (Table 1). Notable genes upregulated in the 
PB-CD31+CD14+ population include FLT4 (vascular endothelial growth factor receptor 4), 
UNC5B (unc-5 netrin receptor B), VCL (vinculin), TGFB1 (or TGFB), CMKLR1 
(chemerin chemokine-like receptor 1) and ICAM1. FLT4 is well established as an 
important mediator of lymphangiogenesis; however, recent research has demonstrated its 
NOTCH-regulated involvement in endothelial sprouting during angiogenesis159,160. 
UNC5B is a receptor expressed in endothelial tip cells during vessel formation where it 
plays a role in neural guidance during development161. Endothelial-specific knockouts of 
Unc5b in mice and zebrafish showed a reduction in fetal arterioles162. Another important 
process in initiation of angiogenesis is the recruitment of vinculin to cell-cell focal adherens 
junctions (FAJ) within the vasculature163. Vinculin, while not necessary for FAJ formation, 
has been shown to be required for FAJ remodeling by cytoskeletal forces163,164. TGFB is 
primarily known for its role in angiogenesis in the promotion of tumor growth. TGFB has 
also been shown to induce angiogenesis when administered subcutaneously in both mice 
and rats165,166. Chemerin induces endothelial proliferation through activation of the 
MAPKinase and Akt signaling pathways167. Lastly, ICAM1 is an important molecule 
involved in polymorphonuclear cell induced angiogenesis168. Each of these factors is 
closely related to increasing angiogenesis through influencing either endothelial migration, 
proliferation or tip-cell formation.  
PB-CD31+CD14- cells significantly differentially express genes promoting vascular 
stability and maturation 
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In the PB-CD31+CD14- cell population, notable expressed genes include PDE3B 
(phosphodiesterase 3B), ROBO4 (roundabout guidance receptor 4), CLDN11 (claudin 11), 
PML (promyelocytic leukemia), ITGB2 (integrin subunit beta 2), JUP (junction 
plakoglobin), SHC1 (src homology 2 domain containing transforming protein 1), ANGPT4 
(angiopoietin 4), CDH5 (vascular endothelial cadherin), RAP1A (ras-related protein krev-
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1), FGFR1 (fibroblast growth factor receptor 1), EGR3 (early growth response 3), ZNF304 
(zing finger protein 304). Expression of PDE3B is regulated by the cAMP signaling 
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Figure 12. Heatmap of angiogenic and immunogenic genes. 
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pathway where it then binds with activated RAPGEF3 where it decreases vascular 
permeability169,170. Similarly, ROBO4 has been shown to interact with UNC5B to reduce 
VEGF signaling, and reduce vascular permeability171. CLDN11 is a cell-cell junction 
protein that is important in maintaining epithelial and endothelial barrier function172. It was 
recently shown that siRNA mediated knockdown of CLDN11 in cultured Schlemm’s canal 
endothelial cells resulted in compromised barrier integrity and increased permeability173. 
PML is most known for its role in tumor suppression and its role in regulating the TNF, 
TGFB, and IFN-alpha signaling pathways174,175. PML represses TGFB which strongly 
induces the secretion of growth factors such as IL1 and the production of collagen and 
fibronectin from macrophages to induce angiogenesis176-180. Knockdown of PML has been 
shown impair angiogenesis by upregulating ITGB1 and reducing endothelial migration181. 
ZNF304, another regulator of ITGB1, has been shown to associate with the ITGB1 
promoter to prevent anoikis in ovarian cancer182. Likewise, ITGB2 is also known to play a 
role in modifying endothelial invasion and matrix remodeling during angiogenesis183,184. 
JUP binds with CDH5 to form adherens junctions and promote adhesion between 
endothelial cells185. FGFR1 signaling is highly expressed during collateral artery growth 
and leads to increased phosphorylation and activation of SHC1186,187. SHC1 is a 
downstream signaling molecule of the angiopoietin receptor TEK/TIE2 where it plays a 
role in collateral remodeling and arteriogenesis188,189. Antithetically, ANGPT4 functions 
as a disruptor of CDH5 and claudin-5 vascular junctions, thereby increasing vascular 
permeability190. Interestingly, RAP1A plays a critical role in attaining mature endothelial 
junctional barrier function191,192. EGR3 has primarily been studied in lymphocyte and 
neuromuscular development; however, EGR3 is also a critical mediator of the endothelial 
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response to VEGF193. The combination of these factors are associated with the 
downregulation of vascular permeability and endothelial migration except for in the case 
of ANGPT4. Overall, CD31+CD14- cells are likely modulators of vascular maturation and 
ECM remodeling. 
CD31+CD14- cells promote cell survival while CD31+CD14+ cells promote immune 
function 
We sought to determine the ontological expression signature of DE genes between 
PB-CD31+CD14- and PB-CD31+CD14+ cells using the (PANTHER) classification system. 
The PANTHER system tests statistical overrepresentation by comparing the representation 
of a functional set of genes within the list of DE genes and comparing that representation 
to a reference list. Using PANTHER, we analyzed DE genes for significant gene 
ontological and pathway function (Figure 14). DE genes from the PB-CD31+CD14- 
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fraction were uniquely significantly associated with the following biological functions: cell 
motility (chemotaxis, cell migration, motility, and projection assembly, regulation of 
locomotion, taxis, negative regulation of cell-cell adhesion), cell survival (apoptotic 
signaling, negative regulation of both apoptotic process and programmed cell death), and 
humoral responses (cytokine-mediated signaling pathway, regulation of signal 
transduction) and an number of major signaling pathways (I-Kappa B/NF- Kappa B, JAK-
STAT, and MAPK signaling cascades) (Figure 14A).  
The strong representation of genes involved in various aspects of cell migration 
supports the notion that PB-CD31+CD14- cells induce chemotaxis and recruitment of 
various cell types. Furthermore, the strong representation of a number of cell survival genes 
indicate that PB-CD31+CD14- cells play an important role in the prevention of necrosis 
Gene	Name p-value Gene	Name p-value Gene	Name p-value Gene	Name p-value
NCF2 1.4531E-09 TFEB 4.7362E-06 BTN3A2 4.1521E-10 ADARB1 1.7097E-06
CTSS 1.2003E-08 ARFIP1 6.5687E-06 BMPR2 6.6684E-09 SLC11A1 2.0274E-06
NOD2 6.5708E-08 PIP5K1C 7.251E-06 PDE3B 1.12E-07 HIST1H2BC 2.0841E-06
DEFB134 1.1462E-07 STX7 7.3966E-06 GBP2 1.136E-07 SLC12A6 2.3468E-06
ARVCF 1.2944E-07 COL4A3BP 8.3449E-06 TNFRSF1A 1.7083E-07 SATB1 2.6786E-06
STX12 2.2883E-07 CSK 8.7199E-06 ARHGAP6 1.7344E-07 RAP1A 3.2137E-06
PCDHB10 2.4337E-07 TNFRSF10D 9.3055E-06 ROBO4 1.7705E-07 FGFR1 4.5253E-06
CD3D 6.3146E-07 SIRPB1 1.0438E-05 PCDHA3 2.3116E-07 IFITM1 5.8766E-06
FLT4 7.0613E-07 CD83 1.1657E-05 ACTN2 2.5376E-07 MYLPF 7.0688E-06
LY86 7.0778E-07 LYST 1.1692E-05 CLDN11 2.7649E-07 IL27RA 7.2967E-06
C5 7.3917E-07 PCDHB13 1.2063E-05 PML 3.2685E-07 PPP3CA 8.2207E-06
UNC5B 1.0863E-06 JAK3 1.6026E-05 ITGB2 3.3936E-07 EGR3 9.1148E-06
STAT5B 1.0983E-06 CCR2 1.623E-05 CARD11 4.1261E-07 PAX5 1.0287E-05
DOCK8 1.1666E-06 APOD 1.6251E-05 NLRP1 4.2619E-07 IL5RA 1.0425E-05
RC3H1 1.2756E-06 LILRA1 1.904E-05 JUP 5.0003E-07 SUSD2 1.0859E-05
VCL 2.3997E-06 PTGER4 2.3862E-05 NLRP6 5.4415E-07 OTUD7B 1.295E-05
TGFBI 2.4601E-06 CDH16 2.59E-05 SHC1 5.9059E-07 ATP6V1B1 1.3115E-05
CCR4 3.5392E-06 TNFSF9 2.6171E-05 IFNW1 6.1835E-07 HIST1H2BI 1.4254E-05
CLTA 3.6435E-06 PDE2A 2.6443E-05 ARF1 6.8735E-07 ELMO2 1.6378E-05
TICAM1 3.9504E-06 PDCD6 3.2558E-05 LILRB4 7.8271E-07 IRF4 1.7687E-05
OAS3 4.1231E-06 ICAM1 3.2683E-05 ITGA3 7.9931E-07 ZNF304 1.9375E-05
CMKLR1 4.441E-06 NCF1 3.3434E-05 ANGPT4 8.0327E-07 RPS6 2.0027E-05
BST1 4.4674E-06 PCDHB14 3.6369E-05 CDH5 1.0205E-06 CNTN4 2.05E-05
TNFSF10 4.6158E-06 TNFRSF10A 3.6381E-05 HIST1H2BG 1.2566E-06 CDHR2 2.18E-05
TRIL 4.7046E-06 CAMK2G 3.78E-05 RHOH 1.6625E-06 HIST1H2BE 2.68E-05
CD31+14+ CD31+14-
Immune	Response
Cell-Cell	Adhesion
Protein	Secretion
Angiogenesis
Endothelial	Differentiation
Cell-Matrix	Adhesion
Table 2. Top 50 differentially expressed genes between PB-CD31+CD14- and PB-
CD31+CD14+ cells and their corresponding ontological groupings.  
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and cell viability. The most insightful information is found in the signaling pathways 
associated with DE genes. The I-Kappa B/NF-Kappa B signaling pathway is a cyclical 
feedback signaling cascade where I-Kappa B is an inhibitor of NF-Kappa B DNA binding 
and NF-Kappa B aids in regulation of I-Kappa B expression194. This signaling pathway is 
known to be activated in smooth muscle cells after arterial injury where it induces 
expression of VCAM-1, MCP-1 and nitric oxide synthase195. VCAM-1 expression in 
endothelial cells is also highly regulated by NF-Kappa B expression196. JAK-STAT 
signaling is a critical signaling medium for a plethora of growth factors and cytokines197. 
The JAK-STAT pathway is responsible for multiple vascular repair processes including 
MMP secretion in SMCs198 and VEGF and VCAM upregulation in endothelial cells199. 
Furthermore, IL-6 and IFNG are well-known STAT activators200. The MAPK signaling 
cascade is critically involved in various complex cellular processes including proliferation, 
differentiation, transformation and apoptosis201. MAPKs are also regulators of the JAK-
STAT pathway due to their role in the phosphorylation and regulation of various STAT 
proteins.  
Notable ontological functions associated with DE genes upregulated in PB-
CD31+CD14+ cells include programmed cell death (T-cell differentiation, extrinsic 
apoptotic signaling and positive regulation of apoptotic process) and protein production 
(positive regulation of macromolecule biosynthetic process and protein metabolic process 
and regulation of cytokine biosynthetic process) (Figure 14B). Interestingly, the significant 
expression of pro-apoptotic genes in PB-CD31+CD14+ cells directly counteracts the anti-
 44 
apoptotic expression signature found in significantly expressed genes from PB-
CD31+CD14- cells. 
Figure 14. Gene ontology of differentially expressed genes between 
CD31+CD14- and CD31+CD14+ cell fractions. Gene ontology set representation 
for DE genes in CD31+CD14- (A) and CD31+CD14+ (B) fractions. Biological 
pathways associated with DE Genes in CD31+CD14- (C) and CD31+CD14+ (D) 
fractions. DE = differentially expressed. GO = gene ontology. 
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CD31+CD14- cells promote cell proliferation while CD31+CD14+ cells initiate stress 
response signalling pathways 
In order to further determine likely mechanism that differentiate PB-CD31+CD14- 
cells from PB-CD31+ CD14+ cells, we examined DE genes for significant involvement in 
major pathways and signaling cascades. Our results show that PB-CD31+CD14- cells are 
strongly associated with activity in the Ras, p38 MAPK, IGF signaling pathways (Figure 
14C). These interconnected pathways initiate and regulate various cell processes involved 
in cell proliferation, migration and metabolism. Ras is a key regulator of cell growth and 
proliferation. Ras activates a series of Raf, MAPK and ERK kinases which, upon 
activation, phosphorylate cytoplasmic targets that stimulate various transcription factors202. 
Interestingly, Ras signaling can promote both cell death and cell survival through c-Myc 
and PI3K, respectively203. Upregulation of p38-MAPK signaling is  required for the 
initiation of apoptosis204. The genes associated with p38-MAPK signaling that are 
upregulated in PB-CD31+CD14- cells are MAP3K5, SRF and MEF2C. MAP3K is an 
activator of p38 signaling and therefore apoptosis; however, SRF and MEF2C are 
suppressors of apoptosis signaling205-208. IGF signaling plays a role in both the upregulation 
and inhibition of apoptosis209,210; however, IGF-kinase B signaling also has the effect of 
stimulating cell proliferation211,212. These data are support the notion that PB-CD31+CD14- 
cells induce cell proliferation and regulate apoptosis. 
Noteworthy pathways associated with genes differentially expressed in the PB-
CD31+CD14+ cells are the netrin mediate axon guidance, oxytocin receptor signaling, 
5HT2 type receptor signaling and association with Huntington and Alzheimer disease 
pathways (Figure 14D). These pathways are all associated with neuronal development, 
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function or disease. This is an interesting result as it implies that PB-CD31+CD14+ cells 
may hold some potential in the improvement of some neurodegenerative disorders. Other 
pathways implicated by DE genes in PB-CD31+CD14+ cells are p53, endothelin signaling, 
adrenalin and noradrenalin biosynthesis and heterotrimeric G-protein signaling pathways. 
The p53 pathway is most researched for its role in tumor suppression; however, p53 also 
has functions in the initiation of apoptosis and stress mediated cell cycle arrest213,214. 
Endothelin signaling plays various roles in the vascular system. Among the most important 
of these functions is endothelin mediated vasoconstriction and vasodilation215. Adrenaline 
and noradrenaline are stress response hormones capable of inducing vasoconstriction and 
counteracting hypotension at low doses216. Heterotrimeric G-protein signaling is upstream 
of VEGF receptor-2 phosphorylation in VEGF signaling217. Heterotrimeric G-protein 
signaling is also a modulator of vascular SMC contraction218. The given representation of 
signaling pathways implies that PB-CD31+CD14+ cells function through the regulation of 
apoptosis, vasoconstriction and endothelial proliferation in response to stress. 
It is important to note that there are a number of gene ontology groupings and 
signaling pathways represented by DE genes from both PB-CD31+CD14- and PB-
CD31+CD14+ cells. Among shared significant GO functions, PB-CD31+CD14+ cells 
displayed notably higher representation of cell adhesion, cell activation and biological 
adhesion (Figure 15A). The higher representation of these GO groups are likely tied to the 
ability of PB-CD31+CD14+ cells to recruit inflammatory cells. Interestingly, while both 
cell fractions show involvement in neovasculogenesis pathways, there are a greater number 
of DE gene for PB-CD31+CD14- cells involved in angiogenesis, FGF and PDGF signaling 
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pathways (Figure 15B). tConversely, a greater number of Wnt and cadherin signaling genes 
were found from the PB-CD31+CD14+ cell fraction (Figure 15B).  
Figure 15. Gene Ontology and Pathway association of differentially expressed 
genes in PB-CD31+14- and PB-CD31+14- cells. DE = differentially expressed. 
GO = gene ontology. 
 48 
Predetermined gene sets for angiogenesis, artery development, vessel remodeling, 
inflammatory response and ECM disassembly were used to determine enrichment. 
Angiogenic genes show favored expression in the CD31+CD14+ fraction while artery 
development, inflammatory and ECM and vascular remodeling genes are more enriched in 
CD31+CD14- cells. None of the gene sets were enriched enough to show significance 
(Figure 16).  
Paracrine factors from PB-CD31+CD14+ cells increase endothelial function. 
In order to evaluate the paracrine effects of the various PB-MNC subpopulations, 
we harvested conditioned medium. An important component of angiogenesis is the 
migration of endothelial cells toward the ischemic region and the formation of collateral 
vessels. We used an in vitro wound healing assay to determine the impact of conditioned 
medium on endothelial migration. Wounds through a monolayer of confluent HUVECs 
were observed over the course of 12 hrs. Wound closure was calculated as the ratio of the 
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Figure 16. GSEA analysis comparing PB-CD31+CD14+ and PB-CD31+CD14- cell 
populations. 
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remaining gap width at 12 hrs and the original gap at 0 hrs (Figure 17A). After statistical 
analysis, the Fischer LSD groupings show that ECs treated with conditioned medium from 
CD31+CD14+ cells do not share a group with either the 0.5% EBM or the CD31- 
conditioned medium treated ECs. These results demonstrate that conditioned medium from 
PB-CD31+CD14+ cells significantly increased wound closure and endothelial migration 
when compared to CD31- CM and negative controls (Figure 17B).  
An endothelial tube formation assay was then used to assess the effects of 
conditioned medium on endothelial function. Fischer LSD groupings show that PB-
CD31+CD14+ CM-treated ECs do not share a grouping with 0.5% EBM CM treated and 
CD31- CM treated ECs. Therefore, CM from PB-CD31+CD14+ cells significantly 
increased endothelial tube formation compared to the CD31- CM and negative controls. 
(Figure 18A and Figure 18B). These data confirm the angiogenic function of PB-
CD31+CD14+ cells.  
Discussion 
In this chapter CD14 was investigated as a selection marker for the isolation and 
enrichment of highly angiogenic cells from PB-CD31+ cells. The purpose for this 
enrichment is to increase the potency and efficacy of cell therapy for critical limb ischemia 
which has historically underperformed either due to a minuscule source population, 
selection through in vitro culture methods corresponding to a lack of defined phenotype or 
the presence of ineffectual cell types90,91. To address these concerns, we hypothesized that 
the CD14+ fraction of CD31+ cells will retain the angiogenic phenotype. Our flow 
cytometry results indicate that the PB-CD31+CD14+ cells contain a significantly higher 
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portion of monocytes, dendritic cells (DC) and hematopoietic stem and progenitor cells. 
Similarly, we determined through FACS analysis that 70% of CD34+ cells and 77% of 
CD133+ cells are also positive for CD14. DCs are the inducers of immunity and hold the 
major function of distinguishing self from foreign219. In particular, the dendritic cell 
population is known to activate CD4 and CD8 T-cells during response to injury220. The 
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Figure 17. Progression of endothelial migration across a scratch wound in 
conditioned medium. (A) Representative images of endothelial migration into 
wound area over 12 hrs. White dotted lines indicate the wound borders at the 
beginning of the assay. (B) Quantification of wound closure after 12 hrs. a, b, c and 
d are the Fischer LSD groupings. n = 6. 
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enrichment of dendritic markers implies some immunomodulatory function of the 
CD31+CD14+ population. CD34 and CD133 are both proposed isolation markers for 
circulating EPCs87. The association between CD14 and EPCs has been previously proposed 
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Figure 18. Effect of conditioned medium from PB cell fractions on endothelial 
tube formation. (A) Representative images of endothelial tube formation in 
conditioned medium from PB cells. (B) Analysis of endothelial tube formation in 
conditioned medium after 9 hrs of culture. a, b and c indicate Fischer LSD 
groupings. n = 6. 
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in the literature132. CD14+ cells have been previously investigated for their expression of 
CD34 and used to treat hindlimb ischemia in mice94,221. Recently, CD14+CD34low cells 
were used in a clinical trial with therapeutic benefits on par with MNC treatment95.  
Given the cellular composition observed in our isolated fractions, we sought to 
characterize their expression profiles using angiogenic growth factors and cytokines. While 
we did observe significantly higher expression of VEGFA and HGF in PB-CD31+CD14+ 
cells compared to PB-CD31+CD14- cells, there was also notably high expression of 
angiogenic factors VEGFA, HGF, ANGPT1 and CXCL8 in the PB-CD31+ population. 
VEGFA is the most potent and well characterized angiogenic factor. Due to is ubiquitous 
presence in the cancer and tumor field, VEGF has gained notoriety for inducing vascular 
growth to the point of pathology where vessels are immature and leaky222. VEGF promotes 
the sprouting of blood vessels and stimulates vasculogenesis through the recruitment of 
precursor cells223,224. CXCL8 both recruits monocytes to the vasculature and stimulates 
VEGF production225,226. CD34+ progenitor cells have also been shown to be responsive to 
the chemotactic effects of CXCL8227. Comparing the expression of PB-CD31+ cells to that 
of PB-CD31+CD14+ cells using the factors we have chosen, we must conclude that while 
the PB-CD31+CD14+ cells do indeed express an angiogenic profile similar to that of PB-
CD31+ cells, they are not more angiogenic than the parent CD31+ population. This 
conclusion correlates with the data shown in the PCA plot and heatmap of angiogenic and 
inflammatory genes. The dendogram from the heatmap clearly demonstrates the 
resemblance between the PB-CD31+ cell population and the PB-CD31+CD14+ cell 
populations. Furthermore, the combination of differentially expressed genes in the PB-
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CD31+CD14+ cell imply an angiogenic phenotype. In particular, FLT4, TGFB, and ICAM1 
are well documented pro-angiogenic proteins. 
CCL2, a chemokine involved in leukocyte recruitment, matrix remodeling and 
arteriogenesis was more highly expressed in PB-CD31+ cells and PB-CD31+CD14+ cells; 
however, this difference was not significant. Matrix remodeling protein MMP9 also 
showed high expression in PB-CD31+ cells without significance. Interestingly, the growth 
factor PDGFB and matrix remodeling enzyme MMP2 were significantly upregulated in 
PB-CD31+CD14- cells. FGF2 was also more highly expressed in PB-CD31+CD14- cells 
compared to PB-CD31+CD14+ cells although this difference was not significant. In the 
literature, these factors are commonly categorized as angiogenic factors due to their known 
role in vascular growth and repair. Upon a more detailed review, the role of these factors 
is to increase vascular conductance through the recruitment of mural cells rather than 
increasing vascular growth. Secreted PDGFB creates a gradient that induces pericyte 
coverage of endothelial cells while FGF2 is a strong inducer of SMC migration228,229.  
FGF2 and PDGFB work together to maintain vascular maturation and stability and promote 
arteriogenesis230-232. Furthermore, MMP2 is a protein commonly used in the literature to 
determine arteriogenic activity due to its involvement in vascular remodeling233,234.  
Among inflammatory cytokines, PB- CD31+CD14- cells appeared to have higher 
expression of inflammatory marker IFNG whereas PB-CD31+CD14+ cells, similar to PB-
CD31+ cells, appeared to have higher expression of inflammatory cytokines TNF and IL10 
although these differences were not significant. IFNG plays a critical role in immunological 
resistance to infection and bacteria235. Likewise, TNF functions to promote inflammation 
through stimulation of proinflammatory responses in capillary endothelial cells236. 
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However, IL10 functions as a repressor of excessive inflammatory responses237. 
Expression of inflammatory factors was fairly mixed between all cell fractions. This mix 
of inflammatory marker expression carried over into the list of differentially expressed 
genes. The majority of genes expressed in both the PB-CD31+CD14- and PB-CD31+CD14+ 
cell populations were inflammatory and had functions involved in recruitment, migration 
and activation of various leukocyte lineages. However, this outcome is expected as each of 
the cell populations are composed of various combinations and representations of 
leukocytes. 
A number of genes significantly differentially expressed in PB-CD31+CD14- cells 
are also heavily involved in regulating the strength of endothelial cell junctions. PDE3B, 
ROBO4, RAPGEF3, JUP, CDH5, and RAP1A all function to strengthen tight junctions or 
adherens junctions between endothelial cells. ANGPT4 was the only expressed gene with 
a known function in the loosening of vascular junctions. Interestingly, a couple of 
significantly differentially expressed genes in PB-CD31+CD14- cells, specifically PML, 
ITGB1, ZNF304 and EGR3, actively disrupt, inhibit or reduce angiogenesis and 
endothelial migration. The strengthening of endothelial bonds and reduction of vascular 
permeability is a major component of arteriogenic remodeling. The conclusion of RT-PCR 
and RNA-Seq data strongly imply a pro-arteriogenic and vascular maturing phenotype of 
PB-CD31+CD14- cells.  
While there were fewer significant unique ontological functions associated with DE 
genes from PB-CD31+CD14+ cells, there was a trend toward the initiation and regulation 
of programmed cell death. This feature was opposite of the apoptosis suppression 
ontological function associated with DE genes from PB-CD31+CD14- cells. Other 
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significant functions of PB-CD31+CD14- cells include the encouragement and promotion 
of cell migration, proliferation and cytokine signaling. These functions are supported by 
the pathway expression associated with DE genes. Interestingly, the representation of 
adrenaline, p53 and heterotrimeric G-protein signaling in PB-CD31+CD14+ cells shows 
that these cells are perhaps an effective population for the local management of stress 
during an ischemic event. There is also a curiously high representation of axonal guidance 
signaling pathways associated with PB-CD31+CD14+ cells; however, the extent of this 
association unclear and outside the scope of this thesis. 
Our quantitative expression data converge on the theory that PB-CD31+CD14+ cells 
are angiogenic, inducing endothelial migration and proliferation, while PB-CD31+CD14- 
cells are arteriogenic, functioning to increase matrix modulation and reduce vascular 
permeability. The results of the endothelial tube formation and migration assays further 
support this premise in that PB-CD31+CD14+ cells secrete various growth factors that work 
to increase endothelial migration and angiogenic function. It was also shown that PB-
CD31+CD14- and PB-CD31+CD14+ play opposing roles in cell survival and programmed 
cell death, respectively. These opposing functions of both cell populations could contribute 
to a reduction of therapeutic efficacy when transplanted together. 
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CHAPTER 4 EVALUATION OF THE THERAPEUTIC POTENTIAL 
OF PERIPHERAL BLOOD MONONUCLEAR CELL FRACTIONS 
Introduction 
Critical limb ischemia (CLI), a state of unrelenting rest pain, is the most severe form 
of peripheral artery disease (PAD). With the current state of medical advancement, CLI 
has a 1-year amputation and mortality rate of 20% and 40%, respectively, for individuals 
without revascularization options5-7. Unfortunately, little is known about the optimal 
treatment of CLI238,239. Pharmacological treatment for PAD is often a complicated task due 
to the likelihood of PAD patients to also exhibit comorbid CVDs that would negatively 
respond to treatment53. Furthermore, endovascular interventions, including angioplasty and 
stenting, are often subject to fracture, restenosis and thrombosis54. An ideal treatment for 
CLI would involve restoration of ischemia through enhanced vessel formation and 
maturation. As a result, neovasculogenic cells have been investigated as alternative 
therapies for CLI. 
Cell Therapy for CLI 
Endothelial progenitor cells have been the most extensively investigated cell 
population for the treatment of CLI. Clinical trials using EPCs have been fairly successful, 
consistently showing statistically significant improvements in vascular perfusion, infarct 
reduction, and transcutaneous oxygen pressure (TcPO2) levels in patients96,97. 
Unfortunately, vascular improvements attributable to EPC injection has been modest98,99. 
The underwhelming performance of EPCs in clinical trials can likely be attributed to a 
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reduction in the proliferative, migrational and functional capacity of EPCs associated with 
cardiovascular disease, aging and smoking100-102. Furthermore, the application of EPCs to 
therapeutic approaches is limited by their broad definition, and the lack of standardized 
methods for isolation and culture90,91. Mesenchymal Stem Cells (MSCs) have also been 
investigated as a cell therapy for CLI. MSCs, similar to EPCs, suffer from a lack of unique 
characterization markers137. Clinical trials of ischemic vascular disease using MNCs have 
demonstrated significant trends toward increased cardiac output, muscle mass, and wound 
healing; however, their therapeutic effects remain marginal120-122. Overall, while the use of 
adult stem cells, including EPCs and MSCs, in clinical trials has been shown to collectively 
decrease limb amputation and increase amputation free survival of critical limb ischemia 
patients, the effects are still marginal120-123. Many clinical trials using EPCs for cardiac and 
vascular repair have been performed using the parent population of bone marrow (BM) and 
peripheral blood (PB) derived mononuclear cells (MNC) under the premise that CD34+ 
EPCs are a subpopulation of transplanted cells92,93. CD34+ cells have also been 
demonstrated to be a subset of PB-CD14+ cells. As a result, PB-CD14+ cells have recently 
been investigated as a therapy for CLI95. The result of this study showed a clear therapeutic 
benefit to the addition of PB-CD14+ cells; however, the therapeutic benefits were on par 
with those of PB-MNC treated patients. Multiple studies using PB-CD14+ cells must be 
established before conclusions may be drawn. 
In this study, we investigate the therapeutic efficacy of PB cells using in vivo mouse 
models of limb ischemia. Extrapolating from data found previously, we hypothesized that 
both the PB-CD31+CD14+ and PB-CD31+CD14- populations would be therapeutically 
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beneficial toward cardiovascular repair. Our results demonstrate the potency of PB-
CD31+CD14+ and PB-CD31+CD14- cells in limb reperfusion. 
Methods 
Isolation and culture of PB cells.  
Human PB samples were collected from healthy male and female volunteers. 
Isolation of MNCs was performed using a modification of a previously reported method147. 
Briefly, each PB sample was diluted with one volume of calcium- and magnesium-free 
phosphate-buffered saline (PBS) containing 2% bovine serum albumin (Miltenyi Biotec, 
Auburn, California), layered on one volume of Histopaque-1077 (Sigma, St. Louis, 
Missouri), and centrifuged at 400 g for 35 min. The MNCs were harvested from the 
interface and washed with magnetic-activated cell sorting (MACS) buffer (Miltenyi 
Biotec). MNCs were centrifuged again at 400 g for 10 min to remove platelets. The cells 
were counted and resuspended in MACS buffer blocking reagent. Human CD14 
microbeads (Miltenyi Biotec) were sequentially added and incubated at 4°C for 20 min. 
The cells were washed and resuspended in MACS buffer. CD14+ and CD14– cells were 
isolated using magnetic LS columns (Miltenyi Biotec) according to the manufacturer’s 
instructions. CD14- cells were then washed with MACS buffer and incubated with Human 
CD31 microbeads (Miltenyi Biotec) at 4°C for 20 min. CD31+CD14- and CD31- cells were 
isolated using magnetic LS columns (Miltenyi Biotec) according to the manufacturer’s 
instructions.  
Hindlimb ischemia surgery and cell injection 
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Athymic BALB/c nude mice (Charles River, Wilmington, MA) were anesthetized 
with 1-3% isoflurane. Two ligations were made to the proximal region of the femoral artery 
near the groin. Two further ligations were made to the distal region of the femoral artery 
near the knee (Figure 19A). The femoral artery was removed beginning with at the distal 
region between the ligations and concluded between the proximal ligations (Figure 19B 
and Figure 19C). 1 x 106 CM-DiI labeled PB-CD31+CD14+, PB-CD31+CD14-, PB-CD31+, 
PB-CD31- or PB-MNCs in 100 µl PBS were intramuscularly injected into the ischemic 
hindlimb of mice to compare their effects. 100 µl PBS was used as a negative/sham control.  
Blood flow measurement in ischemic hindlimbs 
Blood flow of the hindlimb was measured using a Laser Doppler perfusion imager 
(LDPI, Moor instrument, UK) at days 3, 7, 14 and 21. Mean values of perfusion were 
calculated from the stored digital color-coded images. The level of blood flow of the 
ischemic (left) limb was normalized to that of the non-ischemic (right) limb to avoid data 
variations caused by ambient light and temperature. Mice with > 50% perfusion recovery 
at day 3 were considered failed surgical procedures and removed from the study. Outliers 
were determined as LDPI readings that were greater than 2.2 times the interquartile range 
above the third quartile or below the first quartile. Given the need for statistical rigor in the 
Figure 19. Procedural removal of the femoral artery. 
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evaluation of therapeutic treatment and the high patient-to-patient variability that is typical 
with the LDPI assay, we determined ANOVA unsuitable as a statistical method for 
evaluating LDPI data. 
Histological analysis: capillary density 
7 , 21 and 28 days after the injection of cells into ischemic hindlimbs the adductor 
muscles were removed, fixed with 4% paraformaldehyde at 4°C overnight, snap frozen in 
liquid nitrogen and sectioned at 15 µm. To visualize capillaries, the sections were stained 
using FITC conjugated isolectin B4 and DAPI. The stained specimens were visualized 
under conventional inverted epifluorescence microscopy and the capillary density was 
calculated from at least 10 randomly selected fields. 
Histologic analysis: confocal microscopy 
Before euthanasia, mice were intravenously injected with FITC-conjugated 
isolectin B4 (Vector Laboratories). After 10 minutes, mice were euthanized using cervical 
dislocation. The hindlimb tissue was removed, fixed in 4% paraformaldehyde at 4°C for 
16 hours, and incubated in 30% sucrose solution for 24 hours. Tissues were snap frozen in 
liquid nitrogen and imaged at 15 or 50 µm thickness. Nuclei were stained with DAPI 
(Invitrogen). ECs were identified by positive staining for isolectin B4 and their 
characteristic morphology within the vascular structure, and transplanted cells were 
identified by CM-DiI. For arteriogenesis assays, smooth muscle cells were stained with 
rabbit anti-alpha smooth muscle actin primary antibody (Abcam, Cambridge, United 
Kingdom) and Alexa fluor 647 goat anti-rabbit secondary antibody (Invitrogen). 
Incorporation of transplanted cells into the vasculature as ECs was determined using a 
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Zeiss LSM 510 Meta confocal laser scanning microscope and LSM 510 Image software 
(Carl Zeiss, Jena, Germany). 
Statistical Analysis 
All data are represented as means ± S.E.M and statistical analysis was conducted 
in R (Figure 26 and Figure 27). Krusker-Wallis one-way analysis of variance followed by 
pairwise Mann-Whitney U post hoc analysis was used to analyze LDPI data. Other data 
was analyzed using ANOVA followed by multiple comparison with Tukey’s method for 
variables among more than 2 groups. A p value < 0.05 was considered statistically 
significant.  
Results 
PB-CD31+CD14+ and PB-CD31+CD14- cells both increase limb perfusion. 
In order to determine the therapeutic potential of PB- CD31+CD14+/- cells, we treated 
the ischemic hindlimbs of BALB/c nude mice with each isolated cell fraction. By day 14, 
hindlimbs treated with PB-CD31+ or PB-CD31+CD14+ cells had significantly higher 
perfusion compared to PBS, MNC and PB-CD31- cell treated hindlimbs. PB-CD31+CD14- 
cell treated hindlimbs exhibited significantly more perfusion compared to PBS treated 
hindlimbs by day 14. After 21 days, both PB-CD31+CD14- and PB-CD31+CD14+ cell 
treated hindlimbs showed significantly more perfusion compared to PBS, MNC, PB-CD31- 
and PB-CD31+ cell treated hindlimbs. MNC, PB-CD31- and PB-CD31+ cell treated 
hindlimbs were all significantly more perfused compared to PBS treated hindlimbs. 
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Interestingly, both the PB-CD31+CD14- and PB-CD31+CD14+ cell treated hindlimbs were 
more effective at inducing limb perfusion than the parent PB-CD31+ cell treated hindlimbs 
by day 21 (Figure 20).  
PB-CD31+CD14+ cells increase collateral vessel growth 
In order to determine if increased limb perfusion was due to increased collateral 
vessel growth, we performed a capillary density assay. Our results show that day 7 
hindlimbs treated with PB-CD31+CD14+ had significantly increased capillary density 
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Figure 20. Limb perfusion in ischemic hindlimbs. Within each time point: $ = 
significance to PBS, # = significance to CD31-, % = significance to MNC, & = 
significance to CD31+. n = 6 - 15.   
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compared to PBS, MNC and CD31+CD14- treatments. Interestingly, the increased capillary 
density observed in the PB-MNC treated limbs was completely ablated in the PB-
CD31+CD14- treated hindlimbs (Figure 21A and B). In order to determine if the observed 
difference in capillary density formation would persist, we performed a capillary density 
assay at day 28. We observed that not only had the total number of capillaries for each 
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Figure 21. Capillary density in mouse ischemic hindlimbs. (A) Representative 
images of capillary density at day 7. (B) quantification of capillary density images at 
day 7. (A) Representative images of capillary density at day 28. (B) quantification of 
capillary density images at day 28. * p < 0.05, ** p < 0.01. n = 3. 
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group been reduced compared to those observed at day 7, but that there was also no longer 
any significance between the MNC, PB-CD31+CD14- and PB-CD31+CD14+ cell treated 
hindlimbs. However, the capillary density in PBS treated hindlimbs remained at 
significantly lower levels compared to hindlimbs treated with cells (Figure 21C and D). 
PB-CD31+CD14- cells increase arteriole formation and encourage vessel muscularization 
Given the expression patterns observed in the previous aim and effectiveness of 
PB-CD31+CD14+ cells at increasing limb perfusion, we hypothesized that PB-
CD31+CD14- cells must be increasing arteriogenesis in the hindlimbs. In order to measure 
the effect of arteriogenesis, we stained hindlimbs for alpha smooth muscle actin (aSMA). 
aSMA is a marker for smooth muscle cells. If arteriogenesis has been induced, there will 
be a difference in the number of vessels lined with aSMA+ cells. Histological analysis of 
hindlimb tissue harvested at day 28 shows that tissues treated with PB-CD31+CD14- cells 
had significantly increased vascular muscularization compared to PBS, MNC and PB-
CD31+CD14+ cell treated hindlimbs. These data confirm the pro-arteriogenic nature of PB-
CD31+CD14- cells. 
 PB-CD31+CD14+ cells display limited vasculogenic potential 
4-week old hindlimbs were imaged to determine cellular engraftment and examine 
vascular structure. Confocal imaging reveals that PB-CD31+CD14+ cells have limited 
potential for endothelial differentiation and incorporation into the host vasculature (Figure 
23). This supports the hypothesis that circulating progenitor cells are a subset of the PB-
CD31+CD14+ cell population. No such vascular integration was found in PB-CD31+CD14- 
cell treated hindlimbs; however, engrafted PB-CD31+CD14- cells were often found nestled 
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against lectin perfused vessels (Figure 24). It is possible that PB-CD31+CD14- cells may 
position themselves perivascularly in order to direct vascular ECM remodeling as has been 
implicated in their expression profiles. 
Discussion 
We used an athymic BALB/c nude hindlimb ischemia mouse model to determine 
the therapeutic efficacy of PB-CD31+CD14+ and PB-CD31+CD14- cells. Our perfusion 
data showed that PB-CD31+, PB-CD31+CD14- and PB-CD31+CD14+ cell treated 
hindlimbs were capable of increasing limb perfusion at day 14. This support previous 
literature showing that PB-CD31+ cells are angiogenic and are effective at rapidly 
increasing limb perfusion in mouse models of limb ischemia10,11,124. At day 21 we observed 
a significant increase of limb perfusion in both PB-CD31+CD14+ and PB-CD31+CD14- cell 
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Figure 22. Histological analysis of vascular muscularization. White – aSMA, Green 
– lectin, Blue – DAPI. Data represented as mean ± SEM. * p < 0.05. n = 3. 
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treated hindlimbs compared to those of PBS, MNC, PB-CD31- and PB-CD31+ cell injected 
mice by day 21 while MNC, PB-CD31- and PB-CD31+ cell treated hindlimbs were only 
significantly increased compared to PBS treated hindlimbs. Interestingly, the perfusion 
from PB-CD31+CD14- and PB-CD31+CD14+ cell treated groups individually was observed 
to be greater than that of the parent PB-CD31+ population treated hindlimbs. Previous data 
of significantly expressed genes in the PB-CD31+CD14+ and PB-CD31+CD14- populations 
Figure 23. Confocal images of engrafted cells in mouse ischemic hindlimbs. 
CD31+CD14+ cells are shown double positive for lectin and CM-DiI. Red = CM-
DiI, green = FITC-lectin, blue = DAPI. Scale bars = 25 µm. 
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show genes that function through varying pathways; pro-angiogenic and endothelial 
migration inducing for PB-CD31+CD14+ cells and pro-vessel stabilization and maturation 
and for PB-CD31+CD14- cells. A number of these differentially expressed genes in the PB-
CD31+CD14- cell population played active roles in the downregulation of genes highly 
expressed in the PB-CD31+CD14+ cell population as is the case for ROBO4 
downregulating UNC5B, PML repressing TGFB and EGR3 reducing the effectiveness of 
VEGF. This coupled with the inverse apoptosis regulatory functions of each cell population 
support the notion that co-injection of these two cell populations allows them to work 
antagonistically against each other.  
As demonstrated in the capillary density assay, the PB-CD31+CD14+ cells rapidly 
induce the formation of capillaries at early timepoints in limb ischemia; however, this bolus 
of vessel formation is lost by day 28 as is known be an issue in some angiogenic therapies 
such as the delivery of VEGF for peripheral artery disease79. The rapid induction of vessel 
formation often suffers from vascular leakiness and immaturity, lacking the ability to 
Figure 24. Confocal images of engrafted PB-CD31+CD14- cells in mouse ischemic 
hindlimbs. CD31+CD14- cells are shown adjacent to vessel. Red = CM-DiI, green = 
FITC-lectin, blue = DAPI. Scale bars = 25 µm. 
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persist long-term. It is necessary for other factors such as angiopoietins to subsequently 
begin the process of vascular maturation, strengthening the junctions between endothelial 
cells and reducing vascular permeability79. A key player in this process of vascular 
maturation is the SMC; however, SMCs typically arrive later in the neovascularization 
cascade. SMCs “muscularize” small capillaries developing them into arterioles. These 
arterioles have much more lasting potential and are the key to a successful long-term 
vascular therapy. PB-CD31+CD14- cells displayed the ability to recruit SMCs to the 
ischemic region, causing muscularization of 65% of vessels compared to 35% of vessels 
in PB-CD31+CD14+ cell treated hindlimbs. It is known that pericytes and smooth muscle 
cells have a biologically relevant function in regulating endothelial cell growth and 
proliferation240. Furthermore, pathological conditions may encourage SMC mediated 
inhibition of endothelial migration241. An ideal therapy for limb ischemia would cause 
rapid induction of capillary formation in the ischemic region shortly followed by the 
recruitment of SMCs to mature and stabilize functional vessels. It is possible that the 
concentration and injection of cell populations that induce both processes simultaneously 
are counterproductive and the most efficient therapy would be a primary injection of PB-
CD31+CD14+ cells followed by a secondary injection of PB-CD31+CD14+ cells. 
Interestingly, PB-CD31+CD14- cells were able to eventually induce limb perfusion 
despite the lack of rapid capillary network formation in the first 7 days. This implies that 
PB-CD31+CD14- cells have some other compensatory mechanism that initiates tissue and 
vascular repair. It is possible that PB-CD31+CD14- cells increase cell survival and take 
advantage of various ECM remodeling proteins and inflammatory cytokines to initiate 
debridement of the ischemic area. Histological images of engrafted PB-CD31+CD14- cells 
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showed a number of cells positioned perivascularly implying that the injected cells are 
involved in the function or stability of the vasculature; however, such effects are not 
possible to ascertain with the current assays. Another interesting observation was the 
existence of engrafted PB-CD31+CD14+ cells stained positive for perfused lectin.  This 
implies that there is some subset of PB-CD31+CD14+ cells with vasculogenic potential. 
This result coincides with data in the literature where CD14+ cells were shown to 
encompass the elusive highly angiogenic CD34+ cell population94,132. While it is possible 
that PB-CD31+CD14+ cells are capable of contributing to the formation of new collateral 
vessels directly, this phenomenon was rarely observed and it is likely only a minor, 
secondary contributor to the efficacy of the cell therapy as a whole. The primary benefit of 
all injected cell populations is paracrine. 
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CHAPTER 5 SUMMARY AND FUTURE DIRECTIONS 
Cardiovascular disease (CVD) continues to be the major cause of death in the 
developed world. Despite progress in the management of CVD, there is still a great need 
for new treatments and alternative therapies. In critical limb ischemia (CLI), a number of 
cell therapies have been investigated. However, there is a need to overcome the clinical 
limitations of cell therapies such as cell identity, therapeutic potency and isolation of 
adequate cell numbers. This dissertation explored the peripheral blood (PB)- CD31+CD14+ 
and PB-CD31+CD14- populations of cells for their therapeutic potential to treat CLI. 
Identification and Characterization of PB-MNC fractions 
Summary 
In this project, we characterized the phenotype and expression profile of PB-
CD31+CD14+ and PB-CD31+CD14- cells using flow cytometry, qRT-PCR and RNA-seq. 
Our data confirms the highly angiogenic expression profile of PB-CD31+CD14+ cells, 
strongly expressing potent endothelial stimulants such as FLT4, VEGF, HGF, TGFB1 and 
ICAM. Surprisingly, we discovered that PB-CD31+CD14- cells strongly express ECM 
remodeling and vascular maturation proteins such as FGF2, PDGFB, MMP2, ROBO4, 
PML and ITGB1, implying a primarily arteriogenic, vascular stabilizing and maturing 
phenotype. PCA analysis, differential expression analysis and Gene set enrichment 
analysis (GSEA) further support a primarily angiogenic function of PB-CD31+CD14+ cells 
whereas PB-CD31+CD14- cells appear to play a more prominent role in matrix remodeling 
such as SMC and monocytes and endothelial maturation. Assays using conditioned 
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medium work to further solidify the notion that PB-CD31+CD14+ cells secrete angiogenic 
factors that stimulate endothelial movement and activity. 
Limitations 
The major limitation of this project is the lack of assays that evaluate the 
arteriogenic function of cells. Unfortunately, arteriogenesis is a complex process that is 
poorly understood and, as a result there are no recognized assays to decouple angiogenic 
from arteriogenic effects. Presently, the closest method is to examine expression and 
secretion of arteriogenic factors; however, in the case of high throughput systems like 
RNA-seq, there are no established gene ontology sets for arteriogenesis. The development 
of functional assays for arteriogenesis, similar to the tube forming assay for angiogenesis, 
will require greater understanding of the multiple processes involved in initiating and 
prolonging arteriogenesis. A second major limitation is the vague and controversial role of 
the immune response in the vascular repair process. Recruitment of immune cells such as 
monocytes, T-cells, natural killer cells and neutrophils to ischemic tissue to clear 
pathogens, debris and secrete growth factors is critical to the successful initiation of 
cardiovascular repair63. However, imbalances in monocyte/macrophage and T-cell 
polarization are known to aggravate injury despite the initial benefits that come from 
clearing debris242-244. As a result, it becomes difficult to assess the function of any particular 
cell population in cardiovascular repair outside of using animal models. 
In this aim we used robust in vitro expression assays to gain insight into potential 
mechanisms PB cells fractions function through after transplantation into ischemic tissue. 
The limitation of this approach is that it does not take into account the dynamic nature of 
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viable cell in the tissue. PB cells are isolated from presumably healthy blood a are therefore 
expected to have an expression profile consistent with healthy in vivo conditions; however, 
leukocytes often undergo various stages of activation in diseased or ischemic tissue. As a 
result, potential mechanisms of therapeutic efficacy inferred from in vitro assays are only 
reliable regarding the initial stages after cell injection. 
Future Directions 
To overcome the limitations of our study, efforts must be made in the development 
of arteriogenic assays. Perhaps the simplest approach would be to compile a list of all 
known arteriogenic factors for use in RNA sequencing. While use of this list would not be 
able to decouple the angiogenic effects from the arteriogenic ones, such a list would still 
prove useful in the evaluation of a cell type or population’s involvement in the process of 
vessel maturation.  
Another future direction would be to determine the effects of PB cell population on 
other vascular cell types for example, pericytes, fibroblasts and smooth muscle cells. 
Expansion of the in vitro studies to include multiple cells would allow for more conclusions 
to be drawn on which aspects of the neovascularization process are most heavily 
influenced.  
Evaluation of the Therapeutic Potential of PB-MNC fractions 
Summary 
In this aim we sought to determine the therapeutic efficacy of PB cell fractions on 
a mouse model of critical limb ischemia. Our results show that both the PB-CD31+CD14+ 
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and PB-CD31+CD14- fractions of cells strongly induced vascular reperfusion in ischemic 
hindlimbs. Histologically, it was shown that the PB-CD31+CD14+ cells increased limb 
perfusion in part due to the initial increase of collateral vessel growth. PB-CD31+CD14- 
cells were shown to increase SMC recruitment, implying a role in vascular maturity and 
stabilization. 
Limitations 
A major limitation of this study is its use of an acute hindlimb ischemia mouse 
model to evaluate a cell therapy for critical limb ischemia. In general, it is known that 
wildtype mice recover from ischemic injury much more quickly than humans. The use of 
BALB/c background mice helps to circumvent this issue due to their reduced collateral 
vessel growth; however, their innate neovascularization potential far exceeds that of 
humans. Furthermore, atherosclerosis and critical limb ischemia are diseases that do not 
naturally occur in wild type mice. This is compounded with the fact that limb ischemia in 
humans is typically a chronic disease that develops over a lifetime and presents in old age. 
The animal model we used is more indicative of acute limb ischemia. Secondly, we used 
athymic nude mice for our study in order to ablate the typical immune response from 
transplantation of xenogeneic cells. This ablation of the immune response completely 
removes the ability to evaluate the benefits of detriments that transplanted cells may have 
through their expression of inflammatory cytokines.  
Another limitation of this study is the inclusion of so many cell populations that are 
so closely related to each other. We used five cell therapies, four of which originated from 
the first and two of those originating from the third. As a result, the statistical power of the 
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study may have been reduced. Furthermore, it is difficult to draw conclusions about cell 
behavior based on confocal imaging due to selection bias that is inherently introduced in 
the selection of timepoints, slides and regions for imaging. In essence, finding clusters of 
cells within a tissue has no bearing on the overall effects of the cells within that tissue.  
Furthermore, our histology for capillary density and vessel muscularization were 
missing the PB-CD31- and PB-CD31+ cell treatment data points. This limits our study’s 
conclusions about how the PB-CD31+CD14- and PB-CD31+CD14+ cell population interact 
when injected simultaneously. Unfortunately, our samples for the PB-CD31- and PB-
CD31+ treated hindlimbs were harvested at day 21 while our MNC, PB-CD31+CD14- and 
PB-CD31+CD14+ treated hindlimbs were harvested at day 28. Presently, our IACUC 
protocols are more stringent on when animals must be sacrificed and our surgical 
procedures must be altered to accommodate these changes. 
Future Directions 
One way to overcome the limitations of the animal model is to use a chronic 
ischemia mouse model245. This model would more closely match the pathophysiology of 
those patients who are likely to receive our therapy in the future. For the second limitation, 
it was certainly possible to present the data without information regarding the PB-CD31+ 
population as a combination of the PB-CD31-, -CD31+CD14- and –CD31+CD14+ cells 
completely reconstitute the parent PB-MNC population; however, given that previous 
research was done to show the neovasculogenic characteristics of bone marrow and PB-
CD31+ cells, we thought it necessary to include them as a pseudo positive control for 
functional studies. As such, a future study will include the addition of histological samples 
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from PB-CD31- and PB-CD31+ treated hindlimbs in the capillary density and vascular 
muscularization assays. 
Future work should be done to further investigate the arteriogenic function of the 
various cell therapies. One such method is to stain tissue sections at earlier timepoints with 
aSMA to build a temporal framework for when angiogenic and arteriogenic responses are 
initiated and how they progress. This method could be combined with the use of an image 
analysis software to determine vessel size. It may would also be useful to quantify the 
distribution of engrafted cells within the tissue as far as localization and general proximity 
to local vessels. A future direction of this study would be to use an in vivo model of 
arteriogenesis. For example, a recently developed rat model for measuring arteriogenesis 
was developed where the femoral artery and vein are sutured together to form an 
arteriovenous anastomosis. In this model, the hindlimb will experience reduced perfusion 
due to the high resistance of the capillaries. As such, vasodilation and increased vascular 
conductance become the endpoints for the study246.  
It would be insightful to harvest tissue from cell treated hindlimbs at days 7, 14 and 
21 to examine mRNA expression of engrafted cell. This data would help to pinpoint the 
activation state of transplanted cells and elucidate some of the precise pathways that are 
initiated by the various cell therapies. This data could be combined with endogenous 
mRNA expression from the tissue to observe the host response to cell injection. 
Lastly, a future direction for this study could include the use of these cells in other 
cardiovascular disease models such as myocardial infarction or diabetic retinopathy. These 
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cells may also be used in conjunction with biomaterials to aid in long-term engraftment, 
thereby bolstering therapeutic efficacy. 
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APPENDIX A. SUPPLEMENTARY INFORMATION 
Table 3. Sequences of primers used for qRT-PCR 
Gene	 Orientation	 Primer	Sequence	 Company	
VEGFA	
Forward	 GTGCCCACTGAGGAGTCCA	 Eurofins	
Genomics	Reverse	 TCCTATGTGCTGGCCTTGGT	
FGF2	
Forward	 AGCGACCCTCACATCAAGCTA	 Eurofins	
Genomics	Reverse	 CCAGGTAACGGTTAGCACACACT	
ANGPT1	
Forward	 CAGAAAACAGTGGAGAAGATATAACC	 Eurofins	
Genomics	Reverse	 TGCCATCGTGTTCTGGAAGA	
CXCL12	
Forward	 GAAGCGAAAAAACAGTGAATAAACC	 Eurofins	
Genomics	Reverse	 TGGAACCTGAAACCCAGCTG	
HGF	
Forward	 CAATAGTCAATTTACCATCCCGTAAT	 Eurofins	
Genomics	Reverse	 CGTGTTGGAATCCCATTTACAA	
PDGFB	
Forward	 CATCCCGAGGAGCTTTATGAG	 Eurofins	
Genomics	Reverse	 TCCAACTCGGCCCCATCT	
IGF1	
Forward	 CCATGTCCTCCTCGCATCTC	 Eurofins	
Genomics	Reverse	 CGTGGCAGAGCTGGTGAAG	
IL1	
Forward	 GCGACGGTCACCTTCATC	 Eurofins	
Genomics	Reverse	 AGGCACGTGAGCCTCTCTTT	
IL6	
Forward	 GCTGCAGGCACAGAAC	 Eurofins	
Genomics	Reverse	 GCTGCGCAGAATGAGATGAG	
IL8	
Forward	 CCTTTCCACCCCAAATTTATCA	
MWG-Biotech	AG	Reverse	 TTTCTGTGTTGGCGCAGTGT	
IL10	
Forward	 GAGGCTACGGCGCTGTCA	
MWG-Biotech	AG	Reverse	 TCCACGGCCTTGCTCTTG	
IFNG	
Forward	 CCAACGCAAAGCAATACATGA	
MWG-Biotech	AG	Reverse	 TTAGCTGCTGGCGACAGTTC	
TNFA	
Forward	 GGAGAAGGGTGACCGACTCA	 Eurofins	
Genomics	Reverse	 CAGACTCGGCAAAGTCGAGATA	
TGFB	
Forward	 GGAAATTGAGGGCTTTCG	
MWG-Biotech	AG	Reverse	 ACCCGTTGATGTCCACTT	
CXCR4	
Forward	 TGGGTGGTTGTGTTCCAGTTT	
MWG-Biotech	AG	Reverse	 ATGCAATAGCAGGACAGGATGA	
MCP1	
Forward	 GCAATCAATGCCCCAGTCA	
MWG-Biotech	AG	Reverse	 GCCTCTGCACTGAGATCTTCCT	
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Figure 26. General R source code for non-parametric statistical analysis. 
Figure 25. Generalized R source code for RNA-Seq analysis. 
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Figure 27. General R source code for parametric statistical analysis. 
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